Review

GPCR Modulation in Breast Cancer

Rosamaria Lappano [1], Yves Jacquot [2,*] and Marcello Maggiolini [1,*]

[1] Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy; lappanorosamaria@yahoo.it

[2] Laboratoire des Biomolécules, CNRS-UM7203, Sorbonne University, Ecole Normale Supérieure, F-75252 Paris, France

* Correspondence: yves.jacquot@upmc.fr (Y.J.); marcellomaggiolini@yahoo.it or marcello.maggiolini@unical.it (M.M.)

check for updates

Abstract: Breast cancer is the most prevalent cancer found in women living in developed countries. Endocrine therapy is the mainstay of treatment for hormone-responsive breast tumors (about 70% of all breast cancers) and implies the use of selective estrogen receptor modulators and aromatase inhibitors. In contrast, triple-negative breast cancer (TNBC), a highly heterogeneous disease that may account for up to 24% of all newly diagnosed cases, is hormone-independent and characterized by a poor prognosis. As drug resistance is common in all breast cancer subtypes despite the different treatment modalities, novel therapies targeting signaling transduction pathways involved in the processes of breast carcinogenesis, tumor promotion and metastasis have been subject to accurate consideration. G protein-coupled receptors (GPCRs) are the largest family of cell-surface receptors involved in the development and progression of many tumors including breast cancer. Here we discuss data regarding GPCR-mediated signaling, pharmacological properties and biological outputs toward breast cancer tumorigenesis and metastasis. Furthermore, we address several drugs that have shown an unexpected opportunity to interfere with GPCR-based breast tumorigenic signals.

**Keywords:** GPCRs; breast cancer; signal transduction

1. Generalities

G protein-coupled receptors (GPCRs) are hepta-transmembranar proteins playing a crucial role in membrane-initiated signaling processes. They display a key role in a variety of physiological features including cardiac functions, immune responses, metabolism and neurotransmission. They may act alone or in collaboration with other membrane proteins such as, for example, steroid hormone receptors (SHR) [1] and tyrosine kinase receptors (TKR) [2]. As such, GPCRs participate in a plethora of autocrine and paracrine physiological effects.

Typically, the GPCR tertiary structure consists of seven highly hydrophobic transmembrane-spanning α-helices (namely I, II, III, IV, V, VI and VII) that are connected by three intracellular (ICL1, ICL2 and ICL3) and three extracellular (ECL1, ECL2 and ECL3) loops and that are spatially close to form an ~20 Å central cleft [3]. For instance, the gonadotrophin-releasing hormone receptor seems to be characterized by a physical contact between helix 2 and helix 7, through an asparagine (Asn-87) and an aspartate (Asp-318), respectively [4]. Whereas the N-terminal tail of GPCRs is extracellular, the C-terminal extremity is intracellular [5].

A diverse array of GPCR ligands including inorganic ions, amino acids, peptides, proteins, steroids, lipids, nucleosides, nucleotides, biogenic amines and small molecules, as well as GPCR sensori stimuli such as light, tastes and odorants, transduce a wide range of extracellular signals into intracellular messages [6]. When a GPCR is activated, its conformation rapidly changes to allow it to couple to a Gα, Gβ and Gγ-containing heterotrimeric G-protein, which is anchored at the inner face of

the plasma membrane through a myristyl, palmitoyl, farnesyl or geranyl lipidic chain (Scheme 1) [3]. Peptidic sequences also participate in G protein anchoring at the plasma membrane with the C-terminal part of the Gα_S subunit (sequence: Val–Asp–Thr–Glu–Asn–Ile–Arg–Arg–Val–Phe, residues 367 to 376) [7]. These conformational modifications lead to complex ligand-specific multi-states to induce dimerization and, in turn, discrete biological response. GPCRs can thus be considered as rheostats rather than classical off–on switches and their ligands can be considered as biased agonists since they can favor a specific conformation that is responsible for the activation of specific intracellular signaling transduction pathways (Scheme 1) [8,9]. In the GPCR basal state, the Gα subunit is bound to the guanine nucleotide GDP. In the presence of an agonist, GDP is replaced by GTP, allowing the dissociation of the Gα subunit from the $\beta\gamma$ dimer (Scheme 1) [10,11]. Both subunit complexes prompt a network of intracellular effectors including second messenger generating systems, small GTPases and kinase cascades such as MAPK and PI3K/Akt, thus leading to changes in gene transcription and cellular events. Depending on the nature of the α subunit type (i.e., Gα_s, G$\alpha_{i/o}$, G$\alpha_{q/11}$, G$\alpha_{12/13}$), the coupling of GPCR to a G protein may affect diverse intracellular signaling pathways and determine distinct cell fates. To summarize, many GPCRs can stimulate multiple signaling systems and specific ligands can have different relative efficacies towards different transduction pathways. Ultimately, the integration of the functional activity of G protein-regulated networks modulates various cellular functions [12]. By phosphorylating specific serine and threonine residues in the C-terminus of GPCR, G protein kinases (GPK) abrogate GPCR-mediated action and allow the recruitment of β-arrestins, which are in charge of cytosolic internalization and degradation by lysosomes [3,13]. In addition to this regulatory process, GPCR can migrate from the cell surface to endosomes to activate specific genes [14] or can be recycled and sent back to the plasma membrane to display activity (Scheme 1) [15].

(**a**)

Scheme 1. *Cont.*

(b)

Scheme 1. Activation and trafficking process of a G protein-coupled receptor (GPCR). (**A**) When a GPCR is activated, GTP takes the place of GDP at the GPCR-coupled G protein α subunit, allowing its release from the βγ subunit. Then, the complex of GPCR/agonist/α subunit/GTP activates a specific biological response, with the participation of specific partners. (**B**) As a regulatory (desensitization) process, β-arrestin is recruited, allowing GPCR translocation through endosomal pathways where it can be recycled at the membrane or translocated in the nucleus to activate specific genes. GPCR can also be internalized in lysosomes, allowing degradation.

GPCRs constitute the largest superfamily of proteins in the human genome and one of the oldest family of membrane proteins. Their diversity seems to result from the recombination of well-defined amino acids sequences and from the rearrangement of domains that have occurred from a common ancestor, without altering signal functions. These modifications have led to a mosaicism with highly specific receptors, which are supported by a complex phylogenic network [16,17]. Based on their sequence homologies and poor sequence similarities, GPCRs are divided into five classes, i.e., rhodopsin (class A), secretin/adhesion (class B), metabotropic glutamate (class C), pheromone (class D), cAMP (class E) and frizzled/smoothened (class F) receptors [18].

In a pathological context, GPCRs are overexpressed and aberrantly activated, and as such are frequently implicated in many aspects of cancer, including tumor growth, invasion, migration, survival, angiogenesis and metastasis [19–21]. Given the appreciation of their role in cancer, the importance of GPCRs for anticancer drug discovery is undisputable, although very few members have been exploited in pursuit of anticancer therapies [22].

Breast cancer is a highly heterogeneous malignant disease with complex etiological and pathological characteristics. It is the most frequent cancer in women and a major public health problem, with approximately 1.7 million estimated new cases from population-based cancer registries in 2012 worldwide and more than 500,000 related deaths [23]. It has been predicted that the worldwide incidence of female breast tumors will reach 3.2 million new cases per year by 2050 [24], reflecting

the sheer magnitude of breast cancer incidence, its effect on society and the urgent need for new treatments and preventive measures. Triple-negative breast cancers (TNBC), which constitute about 20% of all breast cancers, lack estrogen receptor (ER) and progesterone receptor (PR) expression and do not show gene amplification of the human epidermal growth factor receptor 2 (HER2) [25]. Moreover, they constitute a highly heterogeneous group of tumors that are characterized by various genetic alterations and a lack of validated biomarkers, but that share a distinctly aggressive profile with higher rates of relapse and shorter survival in the metastatic setting, compared to other subtypes of breast cancer [25]. Despite the recent development in subtyping TNBC and the promises of targeted therapies, therapeutic options are limited and cytotoxic chemotherapy remains the mainstay of treatment for these patients [26].

Here, we will discuss the current understanding of certain GPCRs that could be targeted to halt the growth of breast tumors, including TNBC, and that could constitute a new generation of diagnostic tools for breast cancer. In such a context, we will focus on GPCR-based drugs that have been designed, synthesized and evaluated for their efficacy in breast cancer.

2. GPCRs in Breast Cancer: Signaling, Biology and Modulators

2.1. GPER

Estrogens, which are required for normal breast tissue development but which play a well-established role in breast carcinogenesis, mainly act through the estrogen receptors named ERα and ERβ [27]. It is now well documented that estrogen signaling pathways may also occur through the G protein estrogen receptor GPER (originally called GPR30) [28]. This protein of 375 amino acids belongs to the rhodopsin-like (class A) receptor subfamily, as evidenced by the presence of an Asp–Arg–Tyr signature (residues 154 to 156, DRY motif) and an Asn–Pro–Xaa–Xaa–Tyr signature in the C-terminus of helix 7 (residues 320 to 324, NPxxY motif) [29–31]. Diverse experimental studies have demonstrated a role of GPER in the mediation of the stimulatory action prompted either by ER agonists including 17β-estradiol, phytoestrogens (e.g., genistein, coumestrol) and environmental estrogens (e.g., bisphenol A, dichlorodiphenyltrichloroethane) or ER antagonists such as tamoxifen, raloxifen and fulvestrant [32–40]. Synthetic selective and unselective GPER agonists (i.e., G-1, GPER-L1, GPER-L2, carbhydraz) and, as shown in Figure 1, antagonists (i.e., G-15, G-36, MIBE, C4PY, PBX1, PBX2) have been used to dissect the mechanisms governing GPER-mediated biological responses including those prompted in breast cancers [41–48]. Ligand-activated GPER produces rapid cellular signaling events including Ca^{2+} mobilization and kinase cascade activation via the transactivation of the epidermal growth factor receptor (EGFR) [48–50]. As a direct consequence, GPER regulates the expression of a plethora of genes involved in breast cancer cell growth and motility, which in turn are specifically inhibited by GPER antagonists [45,49–51].

Evidence for a role of GPER in breast tissue tumorigenesis and metastasis in vivo was provided using transgenic mouse models of mammary tumorigenesis (MMTV-PyMT, also called PyMT), where a GPER-null mutation (GPER KO/PyMT) was introduced. Tumors from GPER KO/PyMT mice were smaller, with decreased growth and metastatic potential when compared with GPER wild-type (PyMT phenotype) [52]. Accordingly, the tumors issued from GPER KO/PyMT mice were histologically of lower grade than those tumors issued from their wild-type (wt) counterparts, suggesting a less aggressive phenotype [52]. In connection with the above observations, it has been reported that the GPER antagonist G-36 inhibits agonist-induced cell proliferation in explants from normal and cancerous human breast tissues [53]. Analyses of GPER expression in primary breast tumor biopsies also indicate that it is directly linked to tumor size and metastases and, therefore, to pathological and clinical outcomes such as disease progression and poor survival [54]. In addition, GPER expression has been associated with tamoxifen resistance in breast tumors, which is consistent with numerous data indicating the stimulatory action of tamoxifen toward GPER [50,55–57].

Even if the GPER three-dimensional (3D) structure has not yet been experimentally resolved, structural information has emerged from computational approaches [58–61]. For instance, it has been

demonstrated that a conserved proline was responsible for a kink in the seventh trans-membrane helix, allowing conformational changes and G-protein recognition [58]. Whereas the residues Met-1 to Phe-60 (in the N-terminus) correspond to the extracellular part of the protein, the residues Thr-330 to Lys-342, which are in the C-terminus (residues Thr-328 to Lys-375), point towards the inner face of the membrane. These GPER extracellular and intracellular regions are both composed of three loops, as classically observed in GPCRs. The C-terminal tail is in charge of the recruitment of G-protein and β-arrestin, whereas the Phe-208 to Val-225 second loop is essential for the recruitment of ligands [60]. It is of note that cysteins 130 and 207 form a disulfide bond participating in the binding site [60]. Independent studies have also shown that the GPER ligand-binding site is defined by the residues Val-116, Tyr-123, Met-133, Leu-137, Gln-138, Phe-206, Phe-208, Asp-210, Glu-275, Phe-278, Ile-279, Ile-308, Val-309, Phe-314 and Arg-394, where phenylalanines 206, 208 and 278 form a cluster [58–61]. Accordingly, estriol (E3, Figure 1) seems to interact with Thyr-123, Leu-137, Gln-138, Phe-206, Phe-208, Asp-210 and Glu-275 to exert antagonist effects [62]. In this regard, it should be stressed that conformational perturbations at the transmembrane helices II (residues Ala-110 to Ile-114), III (residues Met-141 to Ser-144) and VII (residues Ala-312 to Ser-315) seem to result from ligand binding, suggesting some protein flexibility [61].

Due to the heterogeneity of ligands and due to the absence of well-resolved crystal or NMR complexes, it is difficult to conclude about the structural requirements directing GPER agonism and antagonism. However, by being restricted to quinoleins, the molecule G-1 with an acetyl in position 8 displays agonist action, whereas the molecule G-36, which is characterized by a hindered hydrophobic isopropyl at the same position, is a GPER antagonist (Figure 1) [43,60]. Such an observation strongly suggests that a hydrogen bond-acceptor group in position 8 is required for GPER activation. As the antagonist G-15 is devoid of any substituent at carbon 8 of the quinolein moiety, it can be concluded that a hydrophobic substituent is not an absolute requirement for antagonist action. In fact, and according to modeling studies, substituents at position 8 could point towards cystein 207 to exert steric clash with Arg-394 [41]. The ligand G-15 seems to bind within a pocket of the GPER through an H-bond occurring between an oxygen atom of the methylenedioxyphenyl motif and Glu-54, as well as between the heterocyclic nitrogen of the quinolein moiety and Asn-310. Moreover, it could be involved in a tight salt bridge between the Asp-95 and Arg-155 of the conserved DRY key motif, which contributes to GPER folding and trafficking as well as to the recruitment of G-protein [30,61,63]. G-15 might also generate hydrogen bond with the asparagine 320 of the NPxxY (i.e., NPLIY) motif to stabilize the active state of the protein [63].

**Figure 1.** Structure of GPER antagonists.

2.2. Lysophosphatidic Acid (LPA) and Sphingosine-1-Phosphate (S1P) Receptors

Principally found in extracellular fluids, lysophosphatidic acid (LPA) and its endogenous derivatives exert pleiotropic effects including cell proliferation, migration, invasion, differentiation and adhesion, through at least six class A GPCRs, namely LPA1–6, which also play an important role in mediating malignant behaviors in breast cancer [64,65]. Due to the growing interest in LPA receptors and based on the fact that a well-conserved glutamine (Gln-125) present in the LPA1 binding-pocket governs the interaction with LPA and directs LPA/S1P receptors selectivity, small LPA receptors modulators mimicking LPA have been synthesized [66,67]. In particular, the LPA1/3 antagonist called Debio 0719 (Figure 2a) has been proposed as a promising molecule for breast cancer treatment. This compound, which corresponds to the *R*-isomer of the isoxazolic LPA1/3 competitive inhibitor Ki164425, exhibits higher antagonist effects for LPA1 and LPA3 (IC_{50} = 60 nM and 660 nM, respectively) than the parent molecule Ki16425 drawn in Figure 2a (IC_{50} = 130 nM and 2.3 μM, respectively) [68–70]. In vitro, Debio 0719 inhibits the LPA-dependent invasion of 4T1 mouse mammary cancer cells [69]. In BALB/c mice orthotopically inoculated with 4T1 cells in the mammary gland, the administration of Debio 0719 during the early phase of tumor growth reduces the number of spontaneously disseminated tumor cells to bone, lungs and liver [69,71]. Analogous results were observed using an experimental pulmonary metastatic model consisting of athymic NRC nu/nu mice inoculated with MDA-MB-231 human breast cancer cells [71]. Since Debio 0719 did not affect the growth of primary tumors and tumor-induced angiogenesis [69,71], it could be proposed, therefore, as a metastasis suppressor. Finally, the compound AM095, another Ki16425-derived isoxazole carboxylic acid derivative developed by the Amira Pharmaceuticals Company, showed interesting results on TNBC animal models (Figure 2a) [72].

Sphingosine-1-phosphate (S1P) is involved in tumor initiation, proliferation and metastasis as it behaves as an inflammation, neovascularization, cell growth and survival regulator [73]. This bioactive lipidic mediator mainly acts by interacting with and activating a family of five S1P-specific class A GPCRs (S1P1-5) [74]. The role for all S1P receptors in breast cancer was evidenced from studies demonstrating that their overexpression was linked with poor prognosis in breast tumor patients [75,76].

The simplicity of the structure of S1P offers a paradigm to chemists for pharmacomodulation. As previously highlighted for LPA1 [66], the polar part of S1P seems to be of prime importance for ligand-receptor interactions. Following computational studies, electrostatic contacts occurring between the two basic amino acids Arg-120 and Arg-292 and the phosphate group of S1P, as well as between the ammonium group and the residue Glu-121, have indeed been observed [77]. S1P analogues issued from rational modifications of the lipidic chain have also been synthesized (e.g., [78,79]). The functional S1P receptor antagonist FTY720 (Gilenya®, fingolimod, 2-amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol) becomes active after its phosphorylation by the intracellular type 2 sphingosine kinase, an enzyme that is in charge of the conversion of sphingosine into S1P [80]. FTY720 (Figure 2b) not only reveals immunomodulatory properties (approved as such by the U.S. Food and Drug Administration (FDA) for the treatment of multiple sclerosis), but has also proven efficacy in multiple in vitro and in vivo cancer models including breast tumors [81–84]. However, due to its immune suppressive effects, its future use in oncology seems to be strongly compromised. The potential anticancer mechanism of FTY720 may occur through the inhibition of the proto-oncogene enzyme sphingosine kinase 1 [85] and other targets including the protein phosphatase 2A, cell cycle regulators, cell transporters, autotaxin and the mitochondrial permeability transition pore [85].

Lastly, it should be noted that some information has emerged from structural studies. It has been demonstrated that LPA and SP1 receptors share strong structural similarities but limited local differences [86]. The N-termini of LPA1 and SP1 receptors differ by the presence of a stabilizing disulfide bond occurring between the N-terminal capping helix and the second extracellular loop. Likewise, the short fragment located between the transmembrane helix 1 and the N-terminal capping helix adopts a helical conformation in SP1 but not in LPA1, where it is unstructured [86]. Such structural differences could partially explain not only LPA1/S1P selectivity, but also why the protein LPA1 accepts more structurally divergent ligands than the SP1 receptor.

Figure 2. Structure of (**a**) lysophosphatidic acid (LPA) and (**b**) sphingosine-1-phosphate (S1P) antagonists.

2.3. Prostaglandin E2 Receptors

An aberrant overexpression of the cyclooxygenase (COX)-2, which occurs in 40–50% of invasive breast cancer patients, is associated with a worse prognosis [87]. Likewise, the major COX-2 product found in the tumor milieu is the prostaglandin E2 (PGE2). By acting on a family of four GPCRs (i.e., EP1–4) and more specifically on EP1 and EP4, PGE2 promotes multiple cellular events including the inactivation of host antitumor immune cells, the enhancement of cancer cell migration and invasiveness, tumor-associated angiogenesis and lymphangiogenesis. Thus, it has been postulated that EP antagonists could be of interest for the control of the progression of mammary tumors [87]. Accordingly, non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX2 inhibitors have been shown to prevent the growth of experimental breast tumors (see [87] and the references therein).

The EP1 inhibitor ONO-8711 (Figure 3a) administered at the dose of 800 ppm in female Sprague–Dawley rats exerts apoptotic effects in PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine)-induced mammary gland tumors [88].

EP4, which is widely expressed in primary invasive ductal breast carcinomas, functions through cAMP and PKA pathways and activates PI3K. Accordingly, the blockade of EP4 by diverse small molecules including AH23848, ONO-AE3-208, GW627368X and RQ-15986 (Figure 3b), as well as the triterpenoid saponine Frondoside A, inhibits the proliferation and migration of breast tumor cells, prevents phenotype changes of breast cancer stem cells and reduces breast tumor-initiating capacity, growth and metastasis [89–96]. Taking into account that EP4 antagonists at therapeutic doses are well-tolerated, a phase II trial is currently evaluating the potential of the GW627368X-derived EP4 antagonist AAT007 (also known as RQ-07 or grapiprant, Galliprant®, Figure 3b) with respect to circulating tumor cells and the improvement of outcome in advanced prostate, breast and non-small cell lung cancer alone or in combination with gemcitabine. As EP4 is now identified as a promising new therapeutic target for breast cancer, more potent antagonists such as AAT-008 [97], which show improved pharmacological profiles and bioavailability, have recently been identified.

(**a**)

(**b**)

Figure 3. Structure of (**a**) EP1 and (**b**) EP4 antagonists.

2.4. Protease-Activated Receptors

Coagulant factors such as thrombin and tissue factor (TF) are generated in the tumor microenvironment independently of blood coagulation and induce cell signaling responses through the activation of protease-activated receptors (PARs), which play important roles in neural tube closure, hemostasis, inflammation and the vascular system [98]. PARs also mediate cancer invasion and metastasis by promoting tumor cells migration and angiogenesis and by facilitating cancer cell interactions with host vascular cells including platelets, fibroblasts and blood vessels lining endothelial cells [98]. More precisely, PAR1 and PAR2 have been identified as mediators of breast cancer cell invasion and migration [99,100].

The commercially available PAR1 antagonist SCH 530348 (vorapaxar, Zontivity®, Figure 4a) has been approved by the FDA to reduce thrombotic cardiovascular events in patients with myocardial infarction and peripheral artery disease history but without previous stroke or transient ischemic attack [101]. This drug, which reduces thrombin-induced ovarian cancer cell proliferation [102] and which interferes with the growth and migration of glioma tumor-initiating progenitor cells [103], has not yet been evaluated in breast cancers despite potential advantages in this pathological context.

The PAR1 inhibitor PZ-128 (palmitoyl–Lys–Lys–Ser–Arg–Ala–Leu–Phe–NH$_2$ or P1pal7) belongs to the new family of cell-penetrating membrane-tethered lipopeptides (namely pepducins), which are inspired from the intracellular loops located at the GPCR/G-protein interface [104]. PZ-128 is in a phase II clinical trial for its preventive effects against ischemic and thrombotic complications in patients undergoing cardiac catheterization. Strikingly, it also reduces PAR1-driven tumor growth, angiogenesis and metastatic lesions in breast cancer xenografts [105,106]. Although the question remains whether PZ-128 and other PAR1 inhibitors could be used for the treatment of metastatic breast cancer, pepducins might block the receptor-mediated activation of one specific signaling pathway without affecting others by targeting diverse intracellular loops of PAR1 [107]. In this regard, it should be stressed that the peptidic sequence Pro-Phe-Ile-Ser-Glu-Asp, which has been designed from the *Vibrio cholerae* hemagglutinine protease-mediated cleavage of the mouse PAR1 protein, displays apoptotic effects in MCF-7 breast carcinoma cells by interfering with PAR1 itself, but at a site different from the thrombine-mediated activation site [108].

Concomitant with an increase of the amount of vascular endothelial growth factor (VEGF) and in correlation with enhanced metastatic potential, PAR2 plays also a major role in breast cancer cell proliferation, migration and invasion [100,109]. From a clinical point of view, the elevated expression of PAR2 detected in breast tumor biopsy and metastatic tissues could be linked to an increased malignancy grade and, subsequently, to an overall decrease of the survival rate, as also observed with PAR1 [110]. Some of the PAR2 antagonists also present antitumor properties [111,112]. This is the case of ENMD-1068 (Figure 4b), which is the only commercially available PAR2 antagonist. ENMD-1068 decreases in MCF-7 breast cancer cells the concentrations of granulocyte colony-stimulating factor (GCSF), a highly expressed cytokine correlated with poor survival [113,114]. Recently, structure–activity relationship studies have allowed the identification of promising selective PAR2 inhibitors including derivatives of teleocidin with high efficacy in inhibiting breast tumor cell migration [115]. Whether PAR2 antagonists could be considered as PAR1 antagonists and vice versa is a matter of interest given that PAR2 interacts with PAR1 to form a functional unit implied in breast tumor development [116].

Lastly, the pleckstrin homology (PH)-domain-binding motifs in the C-tails of PAR1 and PAR2, which have been recently recognized as important for PAR-driven breast tumor growth, could serve as novel platforms for future drug therapy design [117].

(**a**)   (**b**)

Figure 4. Structure of (**a**) PAR1 and (**b**) PAR4 antagonists.

2.5. Chemokine Receptors

One of the main chemokine receptors involved in breast growth and metastasis is the type 4 C-X-C chemokine receptor (CXCR4, where C corresponds to cysteine), which accepts for the endogenous ligand the stromal-derived-factor-1 SDF-1 (also called CXCL12) [118–121].

A variety of peptides and small molecules targeting CXCR4 attenuate the growth of breast cancer both in vivo and in vitro. The non-natural 14-mer cyclic peptide TN14003 (Figure 5a), which

contains a D-lysine and a proline to induce a turn conformation stabilized by a cysteine-mediated disulfide bond, was bioinspired from the truncated polyphemusin peptide analogue T140, a CXCR4 specific inverse agonist with anti-HIV properties [122,123]. Remarkably, this compound has the capability to prevent VEGF-mediated tumor angiogenesis induced by the CXCR4/CXCL12 axis in breast tumor xenografts [124] and exerts anti-metastatic activity in breast cancer in cultured cells and animal models [125–127]. The other anti-HIV SDF-1 competitor, Nef-M1, an apoptotic peptide that encompasses the residues 50 to 60 of the HIV-1 Nef protein (sequence: Thr–Asn–Ala–Ala–Cys–Ala–Trp–Leu–Glu–Ala–Gln), not only inhibits the growth of primary breast tumors and related metastasis [128,129], but also prevents breast tumor angiogenesis and epithelial-to-mesenchymal transition [130]. The CXCR4 antagonist GST–NT21MP, a 21-mer synthetic peptide derived from the N-terminal extremity of the viral macrophage inflammatory protein II, also called vMIP-II (NT21MP sequence: Leu–Gly–Ala–Ser–Trp–His–Arg–Pro–Asp–Lys–Cys–Cys–Leu–Gly–tyr–Gln–Lys–Arg–Pro–Leu–Pro, residues 1–21), abrogates SDF-1-induced cell growth, breast cancer cells adhesion and migration, and delays pulmonary metastasis in vivo [131,132]. The SDF-1 peptide analogue CTCE-9908, which consists of a dimer of the first eight amino acids of SDF-1 and in which each Lys–Gly–Val–Ser–Leu–Ser–Tyr–Arg monomer is linked by a C-terminal amidated lysine, behaves as an SDF-1 competitive inhibitor. CTCE-9908 reduces the growth of primary breast tumors and metastasis and markedly enhances the efficacy of other commonly used anticancer therapies such as antiangiogenic (anti-VEGF) antibody and cytotoxic agents (e.g., docetaxel) in mice breast cancer models [133–135]. ALX40-4C (N-α-acetyl-nona-D-arginine amide acetate), which selectively blocks the interaction of SDF-1 with CXCR4, inhibits breast carcinoma cell invasion without decreasing cell viability [136], suggesting a distinct contribution of CXCR4 to the invasion but not to the survival of breast cancer cells. The small cyclic peptide LY2510924 (Figure 5a), which is currently in phase I and II clinical studies for the treatment of advanced refractory solid tumors, inhibits breast tumor metastasis by blocking the migration/homing process to the lung and by inhibiting cell proliferation after tumor cell homing [137]. Among the small CXCR4 antagonists, the cyclam AMD3465 (Figure 5a) inhibits breast cancer growth and metastases by acting on both tumor and immune cells [138]. Furthermore, it reduces breast cancer cell invasiveness and the formation of breast tumors and metastases as well as the infiltration of myeloid CD11b positive cells at metastatic sites and spleen tissue [138]. During the last decade, great interest has particularly been paid to the AMD3465-derived molecule AMD3100 (plerixafor, Mozobil®, Figure 5a), a bicyclam that selectively and reversibly binds within the CXCR4 to disrupt tumor-stroma interactions and that mobilizes hematopoietic stem and progenitor cells to the peripheral blood compartment [139]. Following molecular modeling studies performed with the human protein CXCR4, it was found that the interaction of AMD3100 and AMD3465 with CXCR4 probably results from electrostatic interactions involving the amino acids Asp-171 (transmembrane helix 4), Asp-262 (transmembrane helix 6) and Glu-288 (transmembrane helix 7). Furthermore, one cyclam could interact with Asp-171, whereas the other is sandwiched between the Asp-262 and Glu-288 carboxylic acid functions [140]. The mode of binding of AMD3100 and AMD3465 presents similarities with LY2510924, which requires the residues His-113, Asp-187, Arg-188, Phe-189, Tyr-190, Gln-200 and Glu-288 [137]. Importantly, the FDA has approved AMD3100 for patients with multiple myeloma and non-Hodgkin lymphoma. In the context of breast cancer, AMD3100 (i) inhibits the SDF-1-induced activation of diverse oncogenic signals such as the JAK2/STAT3 signaling pathway [141], (ii) increases cellular sensitivity to carboplatin [142], (iii) cooperates with a pure antiestrogen to decrease breast cancer cell proliferation and migration induced by mesenchymal stem cells [143] and (iv) attenuates hypoxia-dependent metastatic potential [144]. In addition, it limits lung metastases from orthotopically transplanted breast cancer cells [145], abolishes wound-promoted tumor growth and decreases collagen deposition and neo-angiogenesis in mouse models of breast cancer [146]. More recently, AMD3100 has been recommended as a potent radiosensitizer as it augments TNBC cell radiosensitivity and irradiation-induced tumor growth delay [147]. Lastly, the CXCR4 protein epitope POL5551 has been shown to disrupt metastasis and

enhance the chemotherapeutic effects in TNBC [148]. In the same context, the monoclonal antibody Ulocuplumab (BMS-936564 or MDX1338) has shown promising anti-CXCR4 action [149].


Figure 5. Structure of (**a**) CXCR4 and (**b**) CXCR5 peptidic and heterocyclic inhibitors. NaA and ipLys correspond to L-3-(2-naphtyl)alanine and *N*-isopropyl-L-lysine, respectively.

The chemokine ligand 5 (CCL5)/chemokine receptor 5 (CCR5) system also plays a role in promoting breast cancer onset and progression [150]. CCL5 is, indeed, implicated in bidirectional communication patterns between cancerous and normal breast cells as it can be secreted either by tumor or mesenchymal cells that are recruited to the tumor [150]. Moreover, CCR5, which is highly expressed in specific subtypes of breast tumors, has been shown to control breast cancer cell invasiveness and associated metastasis [151].

Maraviroc (Selzentry®, Figure 5b) is the only CCR5 inverse agonist currently approved by the FDA, the European Commission, Health Canada and several other organizations for the treatment of HIV-1-infected patients carrying a CCR5 tropism [152]. Based on the human CCR5 crystal structure, it has been shown that maraviroc occupies a pocket delineated by helices I, II, III, V and VI, where the residues Glu-283 and Tyr-251 interact with the nitrogen atom of the tropane bicyclic motif and the carboxamide nitrogen, respectively [153]. The threonines 295 and 259 also participate in interactions with one of the fluorine atoms and the cyclohexane [153]. The phenyl group fits within an aromatic sub-pocket defined by Phe-109, Phe-112, Tyr-208, Trp-248 and Tyr-251 [153]. Vicriviroc (SCH 417690) is another antiretroviral agent blocking CCR5 (Figure 5b). It shares good oral bioavailability, long half-life, minimal toxicity and excellent antiviral properties in patients infected with CCR5-tropic

HIV-1 [154]. Remarkably, the inhibition of CCR5 by maraviroc and vicriviroc prevents breast cancer cell invasiveness, enhances breast cancer stem killing mediated by chemotherapeutic agents targeting DNA and reduces tumor growth, angiogenesis and metastatic colonization in vivo [151,155,156].

The protein CXCR4 is under the control of the G protein-coupled receptor kinases GRK2 and GRK3. They correspond to negative GPCR regulators that are in charge of the phosphorylation of specific serine and threonine residues prior to the recruitment of β-arrestins to allow receptor internalization (desensitization) and degradation (Scheme 1b) [118]. New approaches devoted to the development of antitumor drugs targeting GRKs have recently been under consideration. As emerging oncomodulators and focusing on ligand-bound GPCRs, only GRKs may prevent the hyperactivation of GPCRs and, therefore, cell proliferation and migration [157]. However, GRK2 induces the activation of the histone deacetylase HDAC6 and, therefore, the growth of luminal and basal breast tumors through Pin1, which is in charge of the *cis-trans* isomerization of the ERα Ser-218 [158,159]. Thus, the inhibition of GRK2 could open a new perspective for the treatment of breast cancer in combination with other chemotherapeutic molecules simultaneously targeting HDAC6 and Pin1 pathways. In this context, GRK2 inhibitors such as the compound 103A have been developed by Takeda Pharmaceuticals (Figure 6) [160]. Likewise, the paroxetine derivative GSK180736A has shown promising results (Figure 6) [161]. GRK3 could also constitute a promising target since it is an important actor in TNBC metastasis [162].


Cpd 103A

GSK 180736

Figure 6. Structure of the GRK2 inhibitors 103A and GSK180736.

Finally, it should be noted that an increase of the CXCR4:GRK3 ratio has been shown to reflect a low metastatic potential in TNBC as it correlates with high amount of CXCR4 and low amount of GRK3 [162]. Hence, CXCR4 as well as GRK3 could be used as biomarkers, not only for the diagnosis of breast tumors but also to define phenotypes and evaluate metastatic risks.

2.6. Angiotensin II Type 1 Receptor

The angiotensin II (AngII) octapeptide is a major actor of the renin-angiotensin system (RAS). Apart from its physiological function, it plays a role in diverse tumors including breast cancer [163]. AngII is produced by the cleavage of the inactive decapeptide precursor angiotensin I (AngI) by a zinc metalloprotease found in the blood circulation or bound to the cell membrane and known as AngI-converting enzyme (ACE) [164]. AngII-mediated biological effects occur through binding to the class A G protein-coupled AngII type 1 and type 2 receptors (AT1R and AT2R, respectively), which have different tissue distribution and which activate various signaling pathways [164]. Most AngII-mediated effects have been attributed to AT1R stimulation, whereas AT2R mainly acts as a counter-regulatory receptor [164]. AngII/AT1R signaling triggers a variety of intracellular effectors, leading to the

regulation of tumor progression-related processes such as cell proliferation, migration, angiogenesis, inflammation and tissue remodeling [165]. AT1R is overexpressed in malignant breast tissue, where it promotes EMT and invasion in vitro, as well as tumor growth and angiogenesis in vivo [166]. Recent interest has focused on the potential anticancer action of ACE inhibitors, which have been successfully used as potent antihypertensive drugs over the last 30 years [167]. By reducing the production of AngII, ACE inhibitors indirectly block AT1R- and AT2R-mediated signaling pathways. However, direct AT1R blockers (ARBs) produce better anticancer clinical results [168]. Molecular modeling studies have revealed that selective AT1R blockers interact at diverse AT1R sites [169]. For instance, the carboxylic acid group and tetrazole ring of valsartan (Figure 7) possibly interact with the Lys-199 of the transmembrane domain TM5, the Ser-109 of the TM3 and the Asn-295 (TM7) of the AT1R, respectively. The carboxylic group, the tetrazole ring and the ethoxy group oxygen of candesartan (Figure 7) seem to interact with the Lys-199 of TM5, the Ser-109 of TM3, the Asn-295 of TM7 and the Gln-257 of TM6 [169]. In the same context, the tetrazole ring and the hydroxymethyl groups of losartan (Figure 7) possibly interact with the Asn-295 of TM7 and the Ser-109 of TM3, respectively [169]. In accordance with the above observations, candesartan is the antagonist that shares the highest binding affinity for AT1R, while losartan shows the weakest affinity as it has the lower number of anchoring points [170]. As it concerns the role displayed by AT1R blockers in the context of breast cancer, it should be noticed that both candesartan and losartan inhibit the AngII-induced expression of VEGF-A, whose expression, along with that of AT1R, was found to correlate with an increase of the microvascular density in breast cancer patients [171]. Moreover, losartan blocks breast tumor growth, invasion, angiogenesis and EMT prompted by AT1R overexpression [166,172], inhibits mammary tumor development and progression to invasive carcinoma [173] and potentiates the doxorubicin and paclitaxel-induced inhibitory effects on breast cancer growth and metastasis [174–176]. The increase of AT1R levels in tamoxifen-resistant breast tumor cells, as compared to sensitive counterparts and tamoxifen sensitivity, were restored by the blockade of AT1R by losartan (Cozaar[®]) [177]. Lastly, it is noteworthy that antineoplastic effects are also exerted by further AT1R blockers such as telmisartan (Micardis[®]) and irbesartan (Avapro[®]) [178,179]. Taken together, these results support the concept of a role for AT1R antagonists in suppressing breast cancer development and progression.


Figure 7. Structure of the AT1R antagonists valsartan, candesartan and losartan.

2.7. Gonadotropin-Releasing Hormone Receptors

By binding to the specific well-conserved class A seven-transmembrane receptor GnRHR, the gonadotropin-releasing hormone GnRH (or luteinizing hormone-releasing hormone LHRH), which is produced in the hypothalamus in a pulsatile manner, stimulates the secretion of gonadotropin when present in the pituitary, thus regulating steroidogenesis and gametogenesis [180]. Briefly, GnRH is a neuroendocrine decapeptide issued from the proteolysis of a preprohormone of 89 amino acids. Its sequence (pyroGlu–His–Trp–Ser–Tyr–Gly–Leu–Arg–Pro–Gly–CONH$_2$) contains a non-proteinogenic pyroglutamic acid (i.e., 5-oxoproline) in the N-terminus and an amidation in the C-terminus.

GnRH analogues induce the downregulation of GnRHR and, therefore, desensitization, whereas competitive antagonists block the secretion of gonadotropin with immediate effects and the absence of hormonal flare (Scheme 1b). Thus, both strategies, which ultimately reduce the amount of circulating gonadotrophins and gonadal steroids, could be used for the treatment of hormone-dependent neoplasms such as those of the prostate, ovary, endometrium and breast [181], in accordance with GnRHR overexpression in extrapituitary steroid-dependent neoplastic tissues [182]. In this regard, it should be stressed that the activation of GnRHRs reduces the cell proliferation and metastasis of cancer cells, indicating a possible direct antitumor activity of GnRH analogues [183]. The suppression of ovarian functions with synthetic GnRH analogues (i.e., agonists) and antagonists has been extensively studied in premenopausal women with early-stage and advanced breast cancers [184].

GnRH peptidic analogues such as goserelin (Zoladex®), buserelin, leuprolide (leuprolein, Eligard®) and triptorelin (Triptodur®) have proven to be as effective as surgical oophorectomy in premenopausal advanced breast cancer [185–188]. As such, they offer similar outcomes compared with tamoxifen, although the endocrine combination appears to be more effective than GnRHR agonists alone [189]. In the case of GnRH analogues, the principal chemical modifications concern the glycine in position 6 as well as the C-terminal extremity. As the GnRH secondary structure is associated with a turn centered around the Gly-6, strategies consisting in introducing conformational constraints to stabilize this turn have been successfuly exploited [190,191]. This glycine has been substituted by D-amino acids such as, for example, a D-Ser(tBu) (e.g., goserelin and buserelin), a D-Leu (e.g., leuprolide) or a D-Trp (e.g., triptorelin), as shown in Figure 8b. Amidation in the C-terminus has also been shown to improve the affinity of the ligands for the receptor [190,191]. Thus, chemical modifications introduced in the GnRH peptidic sequence allow both conformational constraints and affinity improvement, and contribute to improvements of the stability against proteolysis [191]. At present, goserelin is the only GnRH analogue approved by the FDA for the treatment of ER-positive premenopausal metastatic breast cancer [192]. Goserelin, which is a biodegradable sustained-release 3.6 mg depot administered by subcutaneous injection every 28 days, is well-tolerated and associated with less acute toxicity than cytotoxic chemotherapy. Numerous clinical trials in premenopausal women with hormone-sensitive early breast cancer have demonstrated that goserelin either alone or in combination with tamoxifen is at least as effective as cyclophosphamide-, methotrexate- or 5-fluorouracil-based chemotherapy. Likewise, the combination of triptorelin with the anti-aromatase formestane has shown increased antitumor effects [193].

(**a**)

	N_{ter}	1	2	3	4	5	6	7	8	9	10	C_{ter}
GnRH	H	PyroGlu	His	Trp	Ser	Tyr	Gly	Leu	Arg	Pro	Gly	-CONH$_2$
Goserelin	H	PyroGlu	His	Trp	Ser	Tyr	D-Ser(tBu)	Leu	Arg	Pro	-	-CO-NH-NH-CO-NH$_2$
Buserelin	H	PyroGlu	His	Trp	Ser	Tyr	D-Ser(tBu)	Leu	Arg	Pro	-	-CO-NH-C$_2$H$_5$
Leuprolide	H	PyroGlu	His	Trp	Ser	Tyr	D-Leu	Leu	Arg	Pro	-	-CO-NH-C$_2$H$_5$
Triptorelin	H	PyroGlu	His	Trp	Ser	Tyr	D-Trp	Leu	Arg	Pro	-	-CO-NH-CH$_2$-CO-NH$_2$

Pyroglutamic acid (pyroGlu) — D-serine-O-tertiobutyl (D-Ser(tBu)) — D-leucine (D-Leu) — D-tryptophan (D-Trp)

(**b**)

	N_{ter}	1	2	3	4	5	6	7	8	9	10	C_{ter}
GnRH	H	PyroGlu	His	Trp	Ser	Tyr	Gly	Leu	Arg	Pro	Gly	-CONH$_2$
Cetrorelix	Ac	D-Nal	D-Cpa	D-Pal	Ser	Tyr	D-Cit	Leu	Arg	Pro	D-Ala	-CONH$_2$
Ganirelix	Ac	D-Nal	D-Cpa	D-Pal	Ser	Tyr	D-DEhA	Leu	D-DEhA	Pro	D-Ala	-CONH$_2$
Degarelix	Ac	D-Nal	D-Cpa	D-Pal	Ser	DOHP	D-CAP	Leu	Nε-ipLys	Pro	D-Ala	-CONH$_2$
Abarelix	Ac	D-Nal	D-Cpa	D-Pal	Ser	N-MeTyr	D-Asn	Leu	Nε-ipLys	Pro	D-Ala	-CONH$_2$

3-(2'-naphtyl)-D-alanine (D-Nal) — 4-(carbamoylamino-D-phenylalanine (CAP) — 4-chloro-D-phenylalanine (D-Cpa) — 3-(3'-pyridyl)-D-alanine (D-Pal)

D-citrulline (D-Cit) — N,N-diethyl-D-homoarginine (DEhA) — N-isopropyl-L-lysine (Nε–ipLys) — D-alanine (D-Ala) — 4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanine (DOHP)

Figure 8. Structure of (**a**) GnRHR agonists (goserelin, buserelin, leuprolide and triptorelin) and (**b**) GnRHR antagonists (cetrorelix, ganirelix, degarelix, and abarelix). The residues that are subject to pharmacomodulation are indicated in red. The structures and symbols of the non-proteinogenic amino acids of these molecules are specified.

Potent peptidic GnRHR antagonists such as cetrorelix (Cetrotide®), ganirelix (Orgalutran®), degarelix (Firmagon®) and abarelix (Plenaxis®) have been synthesized and clinically tested [194]. To enhance their stability and to improve selectivity in vivo, these compounds share non-proteinogenic amino acids and lack the N-terminal pyroglutamic acid, which is a hallmark of GnRH analogues. GnRH antagonists act by competing with native GnRH in the receptor binding sites, thus causing an immediate suppression of the release of gonadotropins and sex steroids. As such, they have been

evaluated in controlled ovarian hyperstimulation protocols for the prevention of premature luteinizing hormone surge [195] and are successfully used to treat advanced prostate cancer [196]. GnRH antagonists are well-tolerated not only in male but also in female cancers (i.e., endometrial, ovarian and breast cancers) [197]. GnRHR antagonists can induce breast cancer cell apoptosis via the activation of stress-induced mitogen-activated protein kinases and pro-apoptotic proteins [197], as exemplified with cetrorelix, which inhibits the growth of TNBC tumors xenografted in nude mice [198]. In combination with aromatase inhibitors, GnRH antagonists suppress estrogen levels beyond those achieved alone [193]. Due to the interesting pharmacological profile of GnRHR antagonists, a number of non-peptidic (heterocyclic) molecules sharing various pharmacophores, such as, for example, substituted thieno[2,3-*b*]pyridine-4-ones, thieno[2,3-*d*]pyrimidin-2,4-diones, pyrrolo[1,2-*a*]pyrimidin-7-ones, imidazolo[1,2-*a*]pyrimidin-5-ones or uracil derivatives, have been synthesized [199–201].

The GnRHR agonist-binding domain seems to be defined by, amongst others, the Asn-102 (helix 2), the Lys-121 (helix 3) and the Glu-301 (helix 7). Whereas the Asn-102 interacts with the C-terminus amide function of the ligands, the Lys-121 interacts with the His-2 or Trp-3. The Glu-301 seems not only to interact with the Arg-8 through electrostatic contacts but also to modify the ligand conformation [190]. Lastly, it has been proposed distinct agonist and antagonist binding-sites, as the Lys-121 is not involved in the interaction of antagonists [202,203].

2.8. Somatostatin Receptors

Somatostatin (SST or SRIF for somatotropin release-inhibiting factor) is an inhibitory Trp-centered β-turn-containing cyclopeptide that exists under two forms, one of 14 amino acids (Somatostatin-14 or SRIF-14) and one of 28 amino acids (Somatostatin-28 or SRIF-28), as shown in Figure 9a. Produced in the hypothalamus, it functions not only as a neurotransmitter but also as an autocrine/paracrine hormone [204]. In addition, it exerts anti-proliferative effects on both normal and tumor cells [205]. The biological effects of SST are mediated by five receptor subtypes (SSTR1–5), which are expressed in a variety of tumors including breast cancer [206]. As such, they are attractive targets for the imaging and treatment of diverse tumors including neuroendocrine tumors (NETs) [207]. SST analogues, which show prolonged half-life, enhanced receptor subtypes selectivity and increased potency, control tumor growth and metastatization either directly by inducing cell cycle arrest, apoptosis and cell invasion suppression or indirectly by suppressing angiogenesis and the secretion of growth-promoting hormones and growth factors [208].

The synthetic SST analogue octreotide (Sandostatin®, Figure 9b) is highly effective in inhibiting hormone secretion and is used for the treatment of various endocrine and malignant disorders including NETs, acromegaly and gastroenteropancreatic tumors [209–211]. Moreover, it shows inhibitory activity against breast cancer growth in nude mice and in cultured cells either alone or in combination with other drugs [212,213]. This peptide is composed of eight amino-acids, including a non-proteinogenic 2-amino-1,3-dihydroxybutyl and the pharmacophore Phe–Trp–Lys–Thr. With the help of a D-Trp, it is cycled through a disulfide bond to mimic the SST turn conformation [214]. The proliferation of breast cancer cells is also inhibited by the octreotide derivatives BIM 23014 (lanreotide, Somatuline®, Figure 9b) and vapreotide (Sanvar®, Figure 9b), and the doxorubicin-containing molecules AN-162 and AN-238 [215–218]. Phase II studies in breast tumor patients have demonstrated that a continuous subcutaneous infusion of vapreotide, which is commonly used in the treatment of AIDS-related diarrhoea and esophageal variceal bleeding in cirrhotic liver disease patients, can reduce serum levels of growth factors such as prolactin and the insulin like growth factor I (IGF-I), thus encouraging studies combining vapreotide with anti-estrogens, cytotoxic or anti-angiogenic agents [219]. Gratifyingly, a meta-analysis study of phase I and II trials indicates that in patients with metastatic breast cancer, the treatment consisting of the use of somatostatin analogues as first-line therapy is associated with a tumor response of over 40% with few side effects [220]. A number of radiolabeled SST analogue conjugates have also been synthesized not only for treatment but also for diagnostic applications [221,222]. For instance, a [111]In-/^{90}Y-labeled SST analogue, namely

DOTA-D-β-Nal[1]-lanreotide (Dotalan®), has been shown to bind to a broad range of primary human tumors and tumor cell lines including breast cancer cells, presumably through SSTR2-5 [223].

(**a**)

Somatostatin 14

Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys

Somatostatin 28

Ser-Ala-Asn-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys

(**b**)

Figure 9. Structure of (**a**) somatostatin-14 and -28 and (**b**) the inhibitors octreotide, BIM 23014 and vapreotide.

2.9. Gastrin-Releasing Peptide Receptors

The mammalian gastrin-releasing peptide (GRP) is a neuropeptide of 27 amino acids that shares the same C-terminal sequence with the tetradecapeptide bombesin (i.e., His–Leu–Met–NH$_2$). It interacts with a specific receptor, namely GRP-R, to exert several physiological actions including the release of peptide hormones, the secretion of gastric acid, the thermoregulation of enteric motor functions, circadian rhythm, smooth muscle contractions and immune functions [224]. In a high percentage of cancer tissues including breast tumors, GRP-R is overexpressed, allowing the use of GRP-like peptides labeled with β- and/or γ-emitting radionuclides for diagnostic purposes [225,226]. By using single-photon emission computed tomography (SPECT) and positron emission tomography (PET), several studies have demonstrated the usefulness of radiolabeled GRP-R ligands in mouse

breast cancer models as well as in estrogen receptor (ER)-positive breast tumor patients [227–230]. Considering that GRP receptors are overexpressed in a high percentage of ER-positive breast tumors [231], GRP receptor imaging might be used successfully for disease staging and therapy evaluation in ER-positive breast tumor patients. Moreover, GRP elicits mitogenic effects in a number of cancerous tissues including breast tumors [232,233]. Even if there is a limited number of synthetic antagonists, the molecules RC-3940-II (Hca[6],Leu[13]Ψ(CH$_2$-N)Tac[14]-bombesin(6-14)], RC-3950-II [D-Phe[6],Leu[13]Ψ(CH$_2$-N)Tac[14]-bombesin(6-14)) and RC-3095 (Figure 10), which all encompass the bombesin fragment Asn–Gln–Trp–Ala–Val–Gly–His–Leu–Met (residues 6–14), have been shown to decrease the volume of breast cancer xenografts, thus opening new perspectives for the treatment of breast tumors [234–236].

Figure 10. Structure of the GRP-R antagonists RC-3940-II, RC-3950-II and RC-3095, where Tpi corresponds to tetrahydro-1H-pyrido[3,4-*b*]indole, Hca corresponds to desaminophenylalanine and Tac corresponds to thiazolidine-4-carboxylic acid.

2.10. Endothelin Receptors

Endothelins (ET-1, ET-2 and ET-3) are 21-mer peptides containing two stabilizing disulfide bonds. They elicit a number of biological responses by binding to two GPCRs known as endothelin receptor type A (ETAR) and type B (ETBR) [237]. Beyond being the most potent vasoconstrictor in the human cardiovascular system, ET-1 signaling elicits pleiotropic effects in cancer cells and the sourrounding microenvironment by affecting cell proliferation, apoptosis, migration, EMT, chemoresistance and neovascularization [237,238]. Furthermore, an elevated expression of ET-1 and ETAR in breast carcinoma patients is associated with lower survival [239], VEGF expression and angiogenesis [240] and predicts an unfavorable response to neoadjuvant chemotherapy in locally advanced tumors [241].

The use of the selective ETAR antagonists atrasentan (ABT-627, Xinlay® Figure 11) and zibotentan (ZD4054, Figure 11) as well as the dual endothelin receptor inhibitors bosentan (Tracleer®, Figure 11) and macitentan (ACT-064992, Opsumit®, Figure 11) represents the most promising approach for the control of the progression of ET-1-mediated tumors [242]. For instance, atrasentan reduces breast cancer cell invasiveness induced by hypoxia-mediated ET-1 secretion [243] and potentiates the anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells [244]. In the same context, zibotentan exhibits additive anti-migratory and anti-invasive effects when concomitantly used with fulvestrant and aromatase inhibitors on breast cancer cells in vitro and in vivo [245]. The dual antagonist bosentan reduces tumor growth and decreases the levels of pro-inflammatory cytokines and pro-migratory endogenous molecules in immunocompetent mice implanted with mammary carcinoma cells [246]. Likewise, the bosentan derivative macitentan, which represents the next generation of orally active ET receptor antagonists with improved efficacy and tolerability [247], sensitizes experimental breast cancer brain metastases to paclitaxel [248]. Preclinical data obtained with dual ETAR and ETBR antagonists in diverse tumors suggest, therefore, that this class of drugs could be a promising therapeutic option for cancer treatments given that they can target not only tumor cells, which typically express ETAR, but also components of the cancer-associated microenvironment such as vascular, lymphatic and inflammatory cells and fibroblasts, which all express ETBR [238].

Figure 11. Structure of the ETAR antagonists atrasentan, ziboentran, bosentran and macitrentan.

### 2.11. The Hedgehog and Wnt Signaling Pathways

The Hedgehog (Hh) pathway plays important roles in embryonic patterning, stem cell renewal and tissue regeneration and repair [249]. It activates a signaling cascade mediated by the three secreted ligands called Sonic Hedgehog (SHH), Indian Hedgehog (IHH) and Desert Hedgehog (DHH), the 12-pass transmembrane receptor Patched1 (PTCH1) and the GPCR Smoothened (SMO). The glioma-associated oncogene (GLI) transcription factors, which are the effectors of Hh signaling, regulate the expression of target genes, some of which are involved in cancer cell proliferation survival, invasion, migration, epithelial-mesenchymal transition, angiogenesis, metastases and drug resistance [249,250]. More recently, it has been demonstrated that Hh signaling pathways are not only involved in the development of nornal mammary gland, but also in the growth of breast cancer [251]. In patients with invasive ductal breast carcinoma, Hh overexpression is associated with an increased risk of metastasis and with the emergence of a basal-like phenotype [252]. In a mouse model of basal breast cancer, Hh ligands increased tumor growth, induced a poorly differentiated phenotype, accelerated metastasis and reduced survival [252]. Given the contribution of Hh signaling-related processes in a multitude of cancers including breast cancer, several components of this pathway have attracted a great deal of interest as therapeutic targets [250]. Hh signaling pathways can be modulated at different levels: (a) by inhibiting ligand–receptor interactions through antibodies or robotnikinin (Figure 12a); (b) by directly interfering with the SMO; (c) by regulating ciliogenesis and ciliary localization of pathway components and (d) by targeting GLI transcription factors [249]. In this paragraph, we will exclusively pay attention to emerging small molecules antagonizing the protein SMO. Vismodegib (GDC-0449, Erivedge®, Figure 12b) and sonidegib (LDE225, Odomzo®, Figure 12b), which both received FDA approval for the treatment of basal cell carcinoma, inhibit breast cancer cell growth in vitro and in vivo [253–255]. In a phase I clinical trial (GEICAM/2012-12, EDALINE), three of 12 patients with metastatic TNBC were shown to benefit from the combination therapy of sonidegib and docetaxel, with one patient experiencing a complete response [256,257]. Further phase I trials demonstrated that sonidegib in combination with paclitaxel is well-tolerated and may exert antitumor effects in patients with advanced solid tumors including breast cancer [258]. Similar effects were observed in combination with docetaxel in advanced TNBC patients [256,259]. Of note, both vismodegib and sonidegib are currently under clinical investigation in patients with breast tumors and several other SMO antagonists are currently entered in clinical trials for the treatment of various cancer types.

Wnt proteins are a group of highly conserved secreted glycoproteins that are critical for embryo development and adult tissue homeostasis. Frizzled (FZD) proteins, which are seven transmembrane receptors for Wnt ligands and the Wnt co-receptors (namely low-density-lipoprotein receptor-related proteins 5/6 (LRP5/6)) are required for Wnt β-catenin-dependent and -independent signaling pathways [260,261]. The overactivation of Wnt signaling pathways is also implicated in several human diseases including colorectal, hematological and breast cancers [262]. Wnt signaling is activated in over 50% of breast cancer patients and is associated with reduced overall survival [263] and metastasis in TNBCs [264]. Moreover, canonical Wnt ligands and receptors, including FZD7, are frequently overexpressed in breast cancers, while secreted antagonists are silenced [265–267].

Several strategies targeting Wnt signaling in tumors, such as mimics of endogenous Wnt ligands and anti-FZD antibodies, are currently in the clinical testing stage [262,268]. For instance, the inhibition of porcupine (PORCN), which is a membrane-bound *O*-acyltransferase that is required for Wnt secretion and activity, has been indicated as an effective treatment for Wnt-dependent cancers. Accordingly, diverse PORCN inhibitors suppress the growth of mammary tumors in MMTV-Wnt1 transgenic mice [269,270]. Similar inhibitory effects were observed in MMTV-Wnt1 tumors treated with the soluble Wnt inhibitor Fzd8CRD, which consists of the fusion of the Fc region of IgG and the extracellular domain of the receptor FZD8, and LRP6 antagonists or anti-LRP6 antibodies [266,271]. In line with clinical observations revealing that the loss of expression of the protein Wnt-5a in primary breast tumors is associated with a faster tumor spread, the Wnt-5a-mimicking hexapeptide Foxy-5

(sequence: N–Formyl–Met–Asp–Gly–Cys–Glu–Leu–COOH) causes a significant reduction of breast tumor metastases in immunodeficient and immunocompetent mice [272]. Finally, a monoclonal antibody to FZD receptors (OMP-18R5, Vantictumab®) was shown to block the canonical Wnt pathway and to suppress breast cancer cell growth in a human tumor xenograft [273].

(**a**)

Robotnikinin

(**b**)

Vismodegib

Sonidegib

Figure 12. Structure of the compounds interfering with Hedgehog pathways: (**a**) robotnikinin, which binds the extracellular Sonic Hedgehog (SHH) protein and (**b**) vismodegib and sonidegib.

3. Conclusions

GPCRs play an important role in regulating breast cancer initiation and progression as they influence cell survival, growth, migration and metabolism. The overexpression of diverse GPCRs is associated with tumorigenesis and/or metastasis in diverse types of cancer tissues including breast tumors. As such, GPCRs represent attractive targets in breast cancer prevention and treatment. In this review, we have summarized the current knowledge on the action of certain GPCRs in breast cancer and discussed the benefits of GPCR-blockade strategies in this pathological context. Although GPCRs are the largest family of targets for approved drugs, these membrane proteins are of growing interest for the development of anticancer therapies and constitute an expanding field of medical research with exciting perspectives. The evidences reviewed here strongly support the concept that GPCRs can potentially serve as effective targets for breast cancer therapy. In this regard, it should be noted that GPCR-interferring drugs that are currently used for the treatment of others pathologies have shown beneficial effects against breast tumors. This is the case, for instance, of fingolimod (a functional S1P modulator used for the treatment of multiple sclerosis), the EP4 antagonist grapiprant (a veterinary drug used against osteoarthritis in dogs), the antiplatelet PAR1 antagonist varopaxar, anti-HIV-1 drugs

and chemokine receptors inhibitors maraviroc and vicriviroc, in addition to the sartan family members valsartan, candesartan and losartan, which are AT1R and AT2R inhibitors recommended for use in heart failure patients. Ongoing efforts to wholly appreciate the biological activities elicited by GPCRs toward breast tumorigenesis will likely facilitate the development of new innovative pharmacological strategies for treating breast cancer patients.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Wang, D.; Zhao, W.L.; Cai, M.J.; Wang, J.X.; Zaho, X.F. G-protein-coupled receptor controls hormone signaling in cell membrane. *Sci. Rep.* **2015**, *5*, 8675. [CrossRef]
2. Wang, Z. Transactivation of epidermal growth factor receptor by G protein-coupled receptors: Recent progress, challenges and future research. *Int. J. Mol. Sci.* **2016**, *17*, 95. [CrossRef] [PubMed]
3. Audet, M.; Bouvier, M. Restructuring G-protein-coupled receptor activation. *Cell* **2012**, *151*, 14–23. [CrossRef] [PubMed]
4. Zhou, W.; Flanagan, C.; Ballesteros, J.A.; Konvicka, K.; Davidson, J.S.; Weinstein, H.; Millar, R.P.; Sealfon, S.C. A reciprocal mutation supports helix 2 and helix 7 proximity in gonadotrophin-releasing hormone receptor. *Mol. Pharmacol.* **1994**, *45*, 165–170. [PubMed]
5. Venkatakrishnan, A.J.; Deupi, X.; Lebon, G.; Tate, C.G.; Schertler, G.F.; Babu, M.M. Molecular signatures of G protein-coupled receptors. *Nature* **2013**, *494*, 185–194. [CrossRef] [PubMed]
6. Neves, S.R.; Ram, P.T.; Lyengar, R. G protein pathways. *Science* **2002**, *296*, 1636–1639. [CrossRef] [PubMed]
7. Parenti, M.; Viganó, M.; Newman, C.M.H.; Milligan, G.; Magee, A.I. A novel N-terminal motif for palmitoylation of G-protein α subunits. *Biochem. J.* **1993**, *291*, 349–353. [CrossRef]
8. Strange, P.G. Signaling mechanisms of GPCR ligands. *Curr. Opin. Drug Discov. Dev.* **2008**, *11*, 196–202.
9. Rankovic, Z.; Brust, T.F.; Bohn, L.M. Biased agonism: An emerging paradigm in GPCR drug discovery. *Bioorg. Med. Chem. Lett.* **2016**, *26*, 241–250. [CrossRef]
10. Vilardaga, J.P.; Bünemann, M.; Feinstein, T.N.; Lambert, N.; Nikolaev, V.O.; Engelhardt, S.; Lohse, M.J.; Hoffmann, C. GPCR and G proteins: Drug efficacy and activation in live cells. *Mol. Endocrinol.* **2009**, *23*, 590–599. [CrossRef]
11. Cvicek, V.; Godard, W.A., III; Abrol, R. Structure-based sequence alignment of the transmembrane domains of all human GPCRs: Phylogenic, structural and functional implications. *PLoS Comput. Biol.* **2016**, *12*, e1004805. [CrossRef] [PubMed]
12. Wettschureck, N.; Offermanns, S. Mammalian G proteins and their cell type specific functions. *Physiol. Rev.* **2005**, *85*, 1159–1204. [CrossRef] [PubMed]
13. Kang, D.S.; Tian, X.; Benovic, J.L. Role of β-arrestins and arrestin domain-containing proteins in G protein-coupled receptor trafficking. *Curr. Opin. Cell Biol.* **2014**, *27*, 63–71. [CrossRef]
14. Leslie, M. Why endosomes recycle GPCRs. *J. Cell Biol.* **2016**, *214*, 785. [CrossRef]
15. Bowman, S.L.; Shiwarski, D.J.; Puthenveedu, M.A. Distinct G protein-coupled receptor recycling pathways allow spatial control of downstream G protein signaling. *J. Cell Biol.* **2016**, *214*, 797–806. [CrossRef]
16. Allaby, R.G.; Woodwark, M. Phylogenomic analysis reveals extensive phylogenetic mosaicism in the human GPCR superfamily. *Evol. Bioinform. Online* **2007**, *3*, 357–370. [CrossRef] [PubMed]
17. Van den Hoogen, D.J.; Meijer, H.J.G.; Seidl, M.F.; Govers, F. The ancient link between G-protein-coupled receptors and C-terminal phospholipid kinase domains. *mBio* **2018**, *9*, e02119-17. [CrossRef]
18. Hu, G.M.; Mai, T.L.; Chen, C.M. Visualizing the GPCR network: Classification and evolution. *Sci. Rep.* **2017**, *7*, 15495. [CrossRef]
19. Dorsam, R.T.; Gutkind, J.S. G-protein-coupled receptors and cancer. *Nat. Rev. Cancer* **2007**, *7*, 79–94. [CrossRef]
20. Lappano, R.; Maggiolini, M. G protein-coupled receptors: Novel targets for drug discovery in cancer. *Nat. Rev. Drug Discov.* **2011**, *10*, 47–60. [CrossRef]

21. De Francesco, E.M.; Sotgia, F.; Clarke, R.B.; Lisanti, M.P.; Maggiolini, M. G protein-coupled receptors at the crossroad between physiologic and pathologic angiogenesis: Old paradigms and emerging concepts. *Int. J. Mol. Sci.* **2017**, *18*, 2713. [CrossRef] [PubMed]

22. Lappano, R.; Maggiolini, M. Pharmacotherapeutic targeting of G protein-coupled receptors in oncology: Examples of approved therapies and emerging concepts. *Drugs* **2017**, *77*, 951–965. [CrossRef] [PubMed]

23. Tao, Z.; Shi, A.; Lu, C.; Song, T.; Zhang, Z.; Zhao, J. Breast cancer: Epidemiology and etiology. *Cell Biochem. Biophys.* **2015**, *72*, 333–338. [CrossRef] [PubMed]

24. Hortobagyi, G.N.; de la Garza Salazar, J.; Pritchard, K.; Amadori, D.; Haidinger, R.; Hudis, C.A.; Khaled, H.; Liu, M.C.; Martin, M.; Namer, M.; et al. The global breast cancer burden: Variations in epidemiology and survival. *Clin. Breast Cancer* **2005**, *6*, 391–401. [CrossRef] [PubMed]

25. Dent, R.; Trudeau, M.; Pritchard, K.I.; Hanna, W.M.; Kahn, H.K.; Sawka, C.A.; Lickley, L.A.; Rawlinson, E.; Sun, P.; Narod, S.A. Triple-negative breast cancer: Clinical features and patterns of recurrence. *Clin. Cancer Res.* **2007**, *13*, 4429–4434. [CrossRef] [PubMed]

26. Abramson, V.G.; Lehmann, B.D.; Ballinger, T.J.; Pietenpol, J.A. Subtyping of triple-negative breast cancer: Implications for therapy. *Cancer* **2015**, *121*, 8–16. [CrossRef] [PubMed]

27. Huang, B.; Warner, M.; Gustafsson, J.Å. Estrogen receptors in breast carcinogenesis and endocrine therapy. *Mol. Cell. Endocrinol.* **2015**, *418*, 240–244. [CrossRef] [PubMed]

28. Barton, M.; Filardo, E.J.; Lolait, S.J.; Thomas, P.; Maggiolini, M.; Prossnitz, E.R. Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives. *J. Steroid Biochem. Mol. Biol.* **2018**, *176*, 4–15. [CrossRef] [PubMed]

29. Rhee, M.H.; Nevo, I.; Levy, R.; Vogel, Z. Role of the highly conserved Asp-Arg-Tyr motif in signal transduction of CB2 cannabinoid receptor. *FEBS Lett.* **2000**, *466*, 300–304. [CrossRef]

30. Rovati, G.E.; Capra, V.; Neubig, R.R. The highly conserved DRY motif of class A G protein-coupled receptors: Beyond the ground state. *Mol. Pharmacol.* **2007**, *71*, 959–964. [CrossRef]

31. Scheerer, P.; Park, J.H.; Hildebrand, P.W.; Kim, Y.J.; Krauss, N.; Choe, H.W.; Hofmann, K.P.; Ernst, O.P. Crystal structure of opsin in its G-protein-interacting conformation. *Nature* **2008**, *455*, 497–502. [CrossRef] [PubMed]

32. Maggiolini, M.; Vivacqua, A.; Fasanella, G.; Recchia, A.G.; Sisci, D.; Pezzi, V.; Montanaro, D.; Musti, A.M.; Picard, D.; Andò, S. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17β-stradiol and phytoestrogens in breast cancer cells. *J. Biol. Chem.* **2004**, *279*, 27008–27016. [CrossRef] [PubMed]

33. Revankar, C.M.; Cimino, D.F.; Sklar, L.A.; Arterburn, J.B.; Prossnitz, E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. *Science* **2005**, *307*, 1625–1630. [CrossRef] [PubMed]

34. Vivacqua, A.; Bonofiglio, D.; Recchia, A.G.; Musti, A.M.; Picard, D.; Andò, S.; Maggiolini, M. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells. *Mol. Endocrinol.* **2006**, *20*, 631–646. [CrossRef] [PubMed]

35. Vivacqua, A.; Bonofiglio, D.; Albanito, L.; Madeo, A.; Rago, V.; Carpino, A.; Musti, A.M.; Picard, D.; Andò, S.; Maggiolini, M. 17β-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein-coupled-receptor GPR30. *Mol. Pharmacol.* **2006**, *70*, 1414–1423. [CrossRef] [PubMed]

36. Thomas, P.; Dong, J. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: A potential novel mechanism of endocrine disruption. *J. Steroid Biochem. Mol. Biol.* **2006**, *102*, 175–179. [CrossRef]

37. Leblanc, K.; Sexton, E.; Parent, S.; Bélanger, G.; Déry, M.C.; Boucher, V.; Asselin, E. Effects of 4-hydroxytamoxifen, raloxifen and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens. *Int. J. Oncol.* **2007**, *30*, 477–487.

38. Pupo, M.; Pisano, A.; Lappano, R.; Santolla, M.F.; De Francesco, E.M.; Abonante, S.; Rosano, C.; Maggiolini, M. Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-related fibroblasts. *Environ. Health Perspect.* **2012**, *120*, 1177–1182. [CrossRef]

39. Lappano, R.; Pisano, A.; Maggiolini, M. GPER function in breast cancer: An overview. *Front. Endocrinol. (Lausanne)* **2014**, *5*, 66. [CrossRef]

40. Prossnitz, E.R.; Arterburn, J.B. International Union of Basic and Clinical Pharmacology. XCVII. G protein-coupled estrogen receptor and its pharmacologic modulators. *Pharmacol. Rev.* **2015**, *67*, 505–540. [CrossRef]

41. Bologa, C.G.; Revankar, C.M.; Young, S.M.; Edwards, B.S.; Arterburn, J.B.; Kiselyov, A.S.; Parker, M.A.; Tkachenko, S.E.; Savchuck, N.P.; Sklar, L.A.; et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. *Nat. Chem. Biol.* **2006**, *2*, 207–212. [CrossRef] [PubMed]

42. Dennis, M.K.; Burai, R.; Ramesh, C.; Petrie, W.K.; Alcon, S.N.; Nayak, T.K.; Bologa, C.G.; Leitao, A.; Brailoiu, E.; Deliu, E.; et al. In vivo effects of a GPR30 antagonist. *Nat. Chem. Biol.* **2009**, *5*, 421–427. [CrossRef] [PubMed]

43. Dennis, M.K.; Field, A.S.; Burai, R.; Ramesh, C.; Petrie, W.K.; Bologa, C.G.; Oprea, T.I.; Yamaguchi, Y.; Hayashi, S.; Sklar, L.A.; et al. Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. *J. Steroid Biochem. Mol. Biol.* **2011**, *127*, 358–366. [CrossRef] [PubMed]

44. Lappano, R.; Rosano, C.; Santolla, M.F.; Pupo, M.; De Francesco, E.M.; De Marco, P.; Ponassi, M.; Spallarossa, A.; Ranise, A.; Maggiolini, M. Two novel GPER agonists induce gene expression changes and growth effects in cancer cells. *Curr. Cancer Drug Targets* **2012**, *12*, 531–542. [CrossRef] [PubMed]

45. Lappano, R.; Santolla, M.F.; Pupo, M.; Sinicropi, M.S.; Caruso, A.; Rosano, C.; Maggiolini, M. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells. *Breast Cancer Res.* **2012**, *14*, R12. [CrossRef] [PubMed]

46. Sinicropi, M.S.; Lappano, R.; Caruso, A.; Santolla, M.F.; Pisano, A.; Rosano, C.; Capasso, A.; Panno, A.; Lancelot, J.C.; Rault, S.; et al. (6-bromo-1,4-dimethyl-9H-carbazol-3-yl-methylene)-hydrazine (carbhydraz) acts as a GPER agonist in breast cancer cells. *Curr. Top. Med. Chem.* **2015**, *15*, 1035–1042. [CrossRef]

47. Lappano, R.; Rosano, C.; Pisano, A.; Santolla, M.F.; De Francesco, E.M.; De Marco, P.; Dolce, V.; Ponassi, M.; Felli, L.; Cafeo, G.; et al. A calixpyrrole derivative acts as an antagonist to GPER, a G-protein coupled receptor: Mechanisms and models. *Dis. Model. Mech.* **2015**, *8*, 1237–1246. [CrossRef]

48. Maggiolini, M.; Santolla, M.F.; Avino, S.; Aiello, F.; Rosano, C.; Garofalo, A.; Grande, F. Identification of two benzopyrroloxazines acting as selective GPER antagonists in breast cancer cells and cancer-associated fibroblasts. *Future Med. Chem.* **2015**, *7*, 437–448. [CrossRef]

49. Kampa, M.; Pelekanou, V.; Gallo, D.; Notas, G.; Troullinaki, M.; Pediaditakis, I.; Charalampopoulos, I.; Jacquot, Y.; Leclercq, G.; Castanas, E. ERα17p, an ERα P_{295}-T_{311} fragment, modifies the migration of breast cancer cells, through actin cytoskeleton rearrangements. *J. Cell. Biochem.* **2011**, *112*, 3786–3796. [CrossRef]

50. Leiber, D.; Burlina, F.; Byrne, C.; Robin, P.; Piesse, C.; Gonzalez, L.; Leclercq, G.; Tanfin, Z.; Jacquot, Y. The sequence Pro^{295}-Thr^{311} of the hinge region of oestrogen receptor α is involved in ERK1/2 activation via GPR30 in leiomyoma cells. *Biochem. J.* **2015**, *472*, 97–109. [CrossRef]

51. Pandey, D.P.; Lappano, R.; Albanito, L.; Madeo, A.; Maggiolini, M.; Picard, D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. *EMBO J.* **2009**, *28*, 523–532. [CrossRef] [PubMed]

52. Marjon, N.A.; Hu, C.; Hathaway, H.J.; Prossnitz, E.R. G protein-coupled estrogen receptor regulates mammary tumorigenesis and metastasis. *Mol. Cancer Res.* **2014**, *12*, 1644–1654. [CrossRef] [PubMed]

53. Scaling, A.L.; Prossnitz, E.R.; Hathaway, H.J. GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast. *Horm. Cancer* **2014**, *5*, 146–160. [CrossRef] [PubMed]

54. Filardo, E.J. A role for G-protein coupled estrogen receptor (GPER) in estrogen-induced carcinogenesis: Dysregulated glandular homeostasis, survival and metastasis. *J. Steroid Biochem. Mol. Biol.* **2018**, *176*, 38–48. [CrossRef] [PubMed]

55. Ignatov, T.; Eggemann, H.; Semczuk, A.; Smith, B.; Bischoff, J.; Roessner, A.; Costa, S.D.; Kalinski, T.; Ignatov, A. Role of GPR30 in endometrial pathology after tamoxifen for breast cancer. *Am. J. Obstet. Gynecol.* **2010**, *203*, 595.e9–595.e16. [CrossRef] [PubMed]

56. Ignatov, A.; Ignatov, T.; Weissenborn, C.; Eggemann, H.; Bischoff, J.; Semczuk, A.; Roessner, A.; Costa, S.D.; Kalinski, T. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. *Breast Cancer Res. Treat.* **2011**, *128*, 457–466. [CrossRef] [PubMed]

57. Mo, Z.; Liu, M.; Yang, F.; Luo, H.; Li, Z.; Tu, G.; Yang, G. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer. *Breast Cancer Res.* **2013**, *15*, R114. [CrossRef] [PubMed]

58. Rosano, C.; Lappano, R.; Santolla, M.F.; Ponassi, M.; Donadini, A.; Maggiolini, M. Recent advances in the rationale design of GPER ligands. *Curr. Med. Chem.* **2012**, *19*, 6199–6206. [CrossRef] [PubMed]

59. Méndez-Luna, D.; Martínez-Archundia, M.; Maroun, R.C.; Ceballos-Reyes, G.; Fragoso-Vázquez, M.J.; González-Juárez, D.E.; Correa-Basurto, J. Deciphering the GPER/GPR30-agonist and antagonists interactions using molecular modeling studies, molecular dynamics, and docking simulations. *J. Biomol. Struct. Dyn.* **2015**, *33*, 2161–2172. [CrossRef]

60. Rosano, C.; Ponassi, M.; Santolla, M.F.; Pisano, A.; Felli, L.; Vivacqua, A.; Maggiolini, M.; Lappano, R. Macromolecular modelling and docking simulations for the discovery of selective GPER ligands. *AAPS J.* **2016**, *18*, 41–46. [CrossRef]

61. Méndez-Luna, D.; Bello, M.; Correa-Basurto, J. Understanding the molecular basis of agonist/antagonist mechanism of GPER1/GPR30 through structural and energetic analyses. *J. Steroid Biochem. Mol. Biol.* **2016**, *158*, 104–116. [CrossRef] [PubMed]

62. Lappano, R.; Rosano, C.; de Marco, P.; de Francesco, E.M.; Pezzi, V.; Maggiolini, M. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. *Mol. Cell. Endocrinol.* **2010**, *320*, 162–170. [CrossRef] [PubMed]

63. Kim, J.H.; Cho, E.Y.; Min, C.; Park, J.H.; Kim, K.M. Characterization of functional roles of DRY motif in the 2nd intracellular loop of dopamine D2 and D3 receptors. *Arch. Pharm. Res.* **2008**, *31*, 474–481. [CrossRef] [PubMed]

64. Choi, J.W.; Herr, D.R.; Noguchi, K.; Yung, Y.C.; Lee, C.W.; Mutoh, T.; Lin, M.E.; Teo, S.T.; Park, K.E.; Mosley, A.N.; et al. LPA receptors: Subtypes and biological actions. *Annu. Rev. Pharmacol. Toxicol.* **2010**, *50*, 157–186. [CrossRef] [PubMed]

65. Wang, J.; Sun, Y.; Qu, J.; Yan, Y.; Yang, Y.; Cai, H. Roles of LPA receptor signaling in breast cancer. *Expert Rev. Mol. Diagn.* **2016**, *16*, 1103–1111. [CrossRef] [PubMed]

66. Wang, D.A.; Lorincz, Z.; Bautista, D.L.; Liliom, K.; Tigyi, G.; Parrill, A.L. A single amino acid determines lysophospholipid specificity of the $S1P_1$ (EDG1) and LPA_1 (EDG2) phospholipid growth factor receptors. *J. Biol. Chem.* **2001**, *276*, 49213–49220. [CrossRef] [PubMed]

67. Llona-Minguez, S.; Ghassemian, A.; Helleday, T. Lysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolbox. *Prog. Lipid Res.* **2015**, *58*, 51–75. [CrossRef] [PubMed]

68. Ohta, H.; Sato, K.; Murata, N.; Damirin, A.; Malchinkhuu, E.; Kon, J.; Kimura, T.; Tobo, M.; Yamazaki, Y.; Watanabe, T.; et al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. *Mol. Pharmacol.* **2003**, *64*, 994–1005. [CrossRef]

69. David, M.; Ribeiro, J.; Descotes, F.; Serre, C.M.; Barbier, M.; Murone, M.; Clézardin, P.; Peyruchaud, O. Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. *Int. J. Oncol.* **2012**, *40*, 1133–1141. [CrossRef]

70. Sato, T.; Sugimoto, K.; Inoue, A.; Okudaira, S.; Aoki, J.; Tokuyama, H. Synthesis and biological evaluation of optically active Ki16425. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 4323–4326. [CrossRef]

71. Marshall, J.C.; Collins, J.W.; Nakayama, J.; Horak, C.E.; Liewehr, D.J.; Steinberg, S.M.; Albaugh, M.; Vidal-Vanaclocha, F.; Palmieri, D.; Barbier, M.; et al. Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. *J. Natl. Cancer Inst.* **2012**, *104*, 1306–1319. [CrossRef] [PubMed]

72. Brittain, J.E.; Seiders, T.J.; King, C.D. *Preparation of Carbonylamino Isoxazolyl Biphenylacetic Acid Derivatives for Use as Lysophosphatidic Acid Receptor Antagonist*; Amira Pharmaceuticals Inc.: San Diego, CA, USA, 2011; WO2011159550A2.

73. Pyne, N.J.; Pyne, S. Sphingosine 1-phosphate and cancer. *Nat. Rev. Cancer* **2010**, *10*, 489–503. [CrossRef] [PubMed]

74. Pyne, S.; Adams, D.R.; Pyne, N.J. Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances. *Prog. Lipid Res.* **2016**, *62*, 93–106. [CrossRef] [PubMed]

75. Watson, C.; Long, J.S.; Orange, C.; Tannahill, C.L.; Mallon, E.; McGlynn, L.M.; Pyne, S.; Pyne, N.J.; Edwards, J. High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. *Am. J. Pathol.* **2010**, *177*, 2205–2215. [CrossRef] [PubMed]

76. Ohotski, J.; Edwards, J.; Elsberger, B.; Watson, C.; Orange, C.; Mallon, E.; Pyne, S.; Pyne, N.J. Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer. *Int. J. Cancer* **2013**, *132*, 605–616. [CrossRef]

77. Parrill, A.L.; Wang, D.A.; Bautista, D.L.; Van Brocklyn, J.R.; Lorinez, Z.; Fischer, D.J.; Baker, D.L.; Liliom, K.; Spiegel, S.; Tigyi, G. Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate. *J. Biol. Chem.* **2000**, *275*, 39379–39384. [CrossRef]

78. Durgam, G.G.; Virag, T.; Walker, M.D.; Tsukahara, R.; Yasuda, S.; Liliom, K.; van Meeteren, L.A.; Moolenaar, W.H.; Wilke, N.; Siess, W.; et al. Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARγ, and inhibitors of autotaxin. *J. Med. Chem.* **2005**, *48*, 4919–4930. [CrossRef]

79. Cooper, A.; Singh, S.; Hook, S.; Tyndall, J.D.A.; Vernall, A.J. Chemical tools for studying lipid-binding class A G protein-coupled receptors. *Pharmacol. Rev.* **2017**, *69*, 316–353. [CrossRef]

80. Sanchez, T.; Estrada-Hernandez, T.; Paik, J.H.; Wu, M.T.; Venkataraman, K.; Brinkmann, V.; Claffey, K.; Hla, T. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. *J. Biol. Chem.* **2003**, *278*, 47281–47290. [CrossRef]

81. Nagaoka, Y.; Otsuki, K.; Fujita, T.; Uesato, S. Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells. *Biol. Pharm. Bull.* **2008**, *31*, 1177–1181. [CrossRef]

82. Mousseau, Y.; Mollard, S.; Faucher-Durand, K.; Richard, L.; Nizou, A.; Cook-Moreau, J.; Baaj, Y.; Qiu, H.; Plainard, X.; Fourcade, L.; et al. Fingolimod potentiales the effects of sunitinib malate in a rat breast cancer model. *Breast Cancer Res. Treat.* **2012**, *134*, 31–40. [CrossRef] [PubMed]

83. Nagahashi, M.; Yamada, A.; Miyazaki, H.; Allegood, J.C.; Tsuchida, J.; Aoyagi, T.; Huang, W.C.; Terracina, K.P.; Adams, B.J.; Rashid, O.M.; et al. Interstitial fluid sphingosine-1-phosphate in murine mammary gland and cancer and human breast tissue and cancer determined by novel methods. *J. Mammary Gland Biol. Neoplasia* **2016**, *21*, 9–17. [CrossRef]

84. Martin, J.L.; Julovi, S.M.; Lin, M.Z.; de Silva, H.C.; Boyle, F.M.; Baxter, R.C. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade. *Breast Cancer Res.* **2017**, *19*, 90. [CrossRef] [PubMed]

85. White, C.; Alshaker, H.; Cooper, C.; Winkler, M.; Pchejetski, D. The emerging role of FTY720 (fingolimod) in cancer treatment. *Oncotarget* **2016**, *7*, 23106–23127. [CrossRef] [PubMed]

86. Chrencik, J.E.; Roth, C.B.; Terakado, M.; Kurata, H.; Omi, R.; Kihara, Y.; Warshaviak, D.; Nakade, S.; Asmar-Rovira, G.; Mileni, M.; et al. Crystal structure of antagonist bound human lysophosphatidic receptor 1. *Cell* **2015**, *161*, 1633–1643. [CrossRef] [PubMed]

87. Reader, J.; Holt, D.; Fulton, A. Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. *Cancer Metastasis Rev.* **2011**, *30*, 449–463. [CrossRef]

88. Kawamori, T.; Uchiya, N.; Nakatsugi, S.; Watanabe, K.; Ohuchida, S.; Yamamoto, H.; Maruyama, T.; Kondo, K.; Sugimura, T.; Wakabayashi, K. Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP₁ antagonist, on breast cancer development. *Carcinogenesis* **2001**, *22*, 2001–2004. [CrossRef]

89. Ma, X.; Kundu, N.; Rifat, S.; Walser, T.; Fulton, A.M. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. *Cancer Res.* **2006**, *66*, 2923–2927. [CrossRef]

90. Timoshenko, A.V.; Chakraborty, C.; Wagner, G.F.; Lala, P.K. Cox-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. *Br. J. Cancer* **2006**, *94*, 1154–1163. [CrossRef]

91. Yang, L.; Huang, Y.; Porta, R.; Yanagisawa, K.; Gonzalez, A.; Segi, E.; Johnson, D.H.; Narumiya, S.; Carbone, D.P. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. *Cancer Res.* **2006**, *66*, 9665–9672. [CrossRef]

92. Robertson, F.M.; Simeone, A.M.; Mazumdar, A.; Shah, A.H.; McMurray, J.S.; Ghosh, S.; Cristofanilli, M. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. *J. Exp. Ther. Oncol.* **2008**, *7*, 299–312. [PubMed]

93. Xin, X.; Majumder, M.; Girish, G.V.; Mohindra, V.; Maruyama, T.; Lala, P.K. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. *Lab. Investig.* **2012**, *92*, 1115–1128. [CrossRef] [PubMed]

94. Ma, X.; Holt, D.; Kundu, N.; Reader, J.; Goloubeva, O.; Take, Y.; Fulton, A.M. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE₂-mediated immunosuppression and inhibits breast cancer metastasis. *Oncoimmunology* **2013**, *2*, e22647. [CrossRef]

95. Kundu, N.; Ma, X.; Kochel, T.; Goloubeva, O.; Staats, P.; Thompson, K.; Martin, S.; Reader, J.; Take, Y.; Collin, P.; et al. Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties. *Breast Cancer Res. Treat.* **2014**, *143*, 19–31. [CrossRef] [PubMed]

96. Majumder, M.; Xin, X.; Liu, L.; Tutunea-Fatan, E.; Rodriguez-Torres, M.; Vincent, K.; Postovit, L.M.; Hess, D.; Lala, P.K. COX-2 induces breast cancer stem cells via EP4/PI3K/AKT/NOTCH/WNT axis. *Stem Cells* **2016**, *34*, 2290–2305. [CrossRef]

97. Okumura, Y.; Yamagishi, T.; Nukui, S.; Nakao, K. Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. *Bioorg. Med. Chem. Lett.* **2017**, *27*, 1186–1192. [CrossRef] [PubMed]

98. Wojtukiewicz, M.Z.; Hempel, D.; Sierko, E.; Tucker, S.C.; Honn, K.V. Protease-activated receptors (PARs)—Biology and role in cancer invasion and metastasis. *Cancer Metastasis Rev.* **2015**, *34*, 775–796. [CrossRef] [PubMed]

99. Yin, Y.J.; Salah, Z.; Grisaru-Granovsky, S.; Cohen, I.; Even-Ram, S.C.; Maoz, M.; Uziely, B.; Peretz, T.; Bar-Shavit, R. Human protease-activated receptor 1 expression in malignant epithelia: A role in invasiveness. *Arterioscler. Thromb. Vasc. Biol.* **2003**, *23*, 940–944. [CrossRef] [PubMed]

100. Su, S.; Li, Y.; Luo, Y.; Sheng, Y.; Su, Y.; Padia, R.N.; Pan, Z.K.; Dong, Z.; Huang, S. Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. *Oncogene* **2009**, *28*, 3047–3057. [CrossRef] [PubMed]

101. Morrow, D.A.; Braunwald, E.; Bonaca, M.P.; Ameriso, S.F.; Dalby, A.J.; Fish, M.P.; Fox, K.A.; Lipka, L.J.; Liu, X.; Nicolau, J.C.; et al. TRA 2P-TIMI 50 Steering Commitee and Investigators. Varopaxar in the secondary prevention of atherothrombotic events. *N. Engl. J. Med.* **2012**, *366*, 1404–1413. [CrossRef]

102. Chanakira, A.; Westmark, P.R.; Ong, I.M.; Sheehan, J.P. Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer. *Gynecol. Oncol.* **2017**, *145*, 167–175. [CrossRef] [PubMed]

103. Auvergne, R.; Wu, C.; Connell, A.; Au, S.; Cornwell, A.; Osipovitch, M.; Benraiss, A.; Dangelmajer, S.; Guerrero-Cazares, H.; Quinones-Hinojosa, A.; et al. PAR1 inhibition supresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo. *Oncogene* **2016**, *35*, 3817–3828. [CrossRef] [PubMed]

104. Covic, L.; Kuliopulos, A. Protease-activated receptor 1 as therapeutic target in breast, lung, and ovarian cancer: Pepducin approach. *Int. J. Mol. Sci.* **2018**, *19*, 2237. [CrossRef] [PubMed]

105. Boire, A.; Covic, L.; Agarwal, A.; Jacques, S.; Sherifi, S.; Kuliopulos, A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. *Cell* **2005**, *120*, 303–313. [CrossRef] [PubMed]

106. Yang, E.; Boire, A.; Agarwal, A.; Nguyen, N.; O'Callaghan, K.; Tu, P.; Kuliopulos, A.; Covic, L. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. *Cancer Res.* **2009**, *15*, 6223–6231. [CrossRef]

107. Cisowski, J.; O'Callaghan, K.; Kuliopulos, A.; Yang, J.; Nguyen, N.; Deng, Q.; Yang, E.; Fogel, M.; Tressel, S.; Foley, C.; et al. Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. *Am. J. Pathol.* **2011**, *179*, 513–523. [CrossRef]

108. Ray, T.; Kar, D.; Pal, A.; Mukherjee, S.; Das, C.; Pal, A. Molecular targeting of breast and colon cancer cells by PAR1 mediated apoptosis through a novel pro-apoptotic peptide. *Apoptosis* **2018**, *23*, 679–694. [CrossRef]

109. Liu, Y.; Mueller, B.M. Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways. *Biochem. Biophys. Res. Commun.* **2006**, *344*, 1263–1270. [CrossRef]

110. Lidfeldt, J.; Bendahl, P.O.; Forsare, C.; Malmström, P.; Fernö, M.; Belting, M. Protease activated receptors 1 and 2 correlate differently with breast cancer aggressiveness depending on tumor ER status. *PLoS ONE* **2015**, *10*, e0134932. [CrossRef]

111. Carneiro-Lobo, T.C.; Schaffner, F.; Disse, J.; Ostergaard, H.; Francischetti, I.M.; Monteiro, R.Q.; Ruf, W. The tick-derived inhibitor Ixolaris prevents tissue factor signaling on tumor cells. *J. Thromb. Haemost.* **2012**, *10*, 1849–1858. [CrossRef]

112. Jiang, Y.; Yau, M.K.; Lim, J.; Wu, K.C.; Xu, W.; Suen, J.Y.; Fairlie, D.P. A potent antagonist of protease-activated receptor 2 that inhibits multiple signaling functions in human cancer cells. *J. Pharmacol. Exp. Ther.* **2018**, *364*, 246–257. [CrossRef] [PubMed]

113. Carvalho, É.; Hugo de Almeida, V.; Rondon, A.M.R.; Possik, P.A.; Viola, J.P.B.; Monteiro, R.Q. Protease-activated receptor 2 (PAR2) upregulates granulocyte colony stimulating factor (G-CSF) expression in breast cancer cells. *Biochem. Biophys. Res. Commun.* **2018**, *504*, 270–276. [CrossRef] [PubMed]

114. Hollmén, M.; Roudnicky, F.; Karaman, S.; Detmar, M. Characterization of macrophage—Cancer cell crosstalk in estrogen receptor positive and triple negative breast cancer. *Sci. Rep.* **2015**, *5*, 9188. [CrossRef] [PubMed]

115. Stein, J.; Stahn, S.; Neudörfl, J.M.; Sperlich, J.; Schmalz, H.G.; Teusch, N. Synthetic indolactam V analogues as inhibitors of PAR2-induced calcium mobilization in triple-negative breast cancer cells. *ChemMedChem* **2018**, *13*, 147–154. [CrossRef] [PubMed]

116. Jaber, M.; Maoz, M.; Kancharla, A.; Agranovich, D.; Peretz, T.; Grisaru-Granovsky, S.; Uziely, B.; Bar-Shavit, R. Protease-activated-receptor-2 affects protease-activated-receptor-1-driven breast cancer. *Cell. Mol. Life Sci.* **2014**, *71*, 2517–2533. [CrossRef] [PubMed]

117. Kancharla, A.; Maoz, M.; Jaber, M.; Agranovich, D.; Peretz, T.; Grisaru-Granovsky, S.; Uziely, B.; Bar-Shavit, R. PH motifs in PAR1&2 endow breast cancer growth. *Nat. Commun.* **2015**, *6*, 8853.

118. Müller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M.E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S.N.; et al. Involvement of chemokine receptors in breast cancer metastasis. *Nature* **2001**, *410*, 50–56. [CrossRef]

119. Dewan, M.Z.; Ahmed, S.; Iwasaki, Y.; Ohba, K.; Toi, M.; Yamamoto, N. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. *Biomed. Pharmacother.* **2006**, *60*, 273–276. [CrossRef]

120. Zhang, Z.; Ni, C.; Chen, W.; Wu, P.; Wang, Z.; Yin, J.; Huang, J.; Qiu, F. Expression of CXCR4 and breast cancer prognosis: A systematic review and meta-analysis. *BMC Cancer* **2014**, *14*, 49. [CrossRef]

121. Xu, C.; Zhao, H.; Chen, H.; Yao, Q. CXCR4 in breast cancer: Oncogenic role and therapeutic targeting. *Drug Des. Dev. Ther.* **2015**, *9*, 4953–4964.

122. Tamamura, H.; Omagari, A.; Hiramatsu, K.; Gotoh, K.; Kanamoto, T.; Xu, Y.; Kodama, E.; Matsuoka, M.; Hattori, T.; Yamamoto, N.; et al. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 1897–1902. [CrossRef]

123. Zhang, W.B.; Navenot, J.M.; Haribabu, B.; Tamamura, H.; Hiramatu, K.; Omagari, A.; Pei, G.; Manfredi, J.P.; Fujii, N.; Broach, J.R.; et al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. *J. Biol. Chem.* **2002**, *277*, 24515–24521. [CrossRef] [PubMed]

124. Liang, Z.; Brooks, J.; Willard, M.; Liang, K.; Yoon, Y.; Kang, S.; Shim, H. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. *Biochem. Biophys. Res. Commun.* **2007**, *359*, 716–722. [CrossRef] [PubMed]

125. Tamamura, H.; Hori, A.; Kanzaki, N.; Hiramatsu, K.; Mizumoto, M.; Nakashima, H.; Yamamoto, N.; Otaka, A.; Fujii, N. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. *FEBS Lett.* **2003**, *550*, 79–83. [CrossRef]

126. Liang, Z.; Wu, T.; Lou, H.; Yu, X.; Taichman, R.S.; Lau, S.K.; Nie, S.; Umbreit, J.; Shim, H. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. *Cancer Res.* **2004**, *64*, 4302–4308. [CrossRef]

127. Lefort, S.; Thuleau, A.; Kieffer, Y.; Sirven, P.; Bieche, I.; Marangoni, E.; Vincent-Salomon, A.; Mechta-Grigoriou, F. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients. *Oncogene* **2017**, *36*, 1211–1222. [CrossRef]

128. Bumpers, H.; Huang, M.B.; Katkoori, V.; Manne, U.; Bond, V. Nef-M1, a CXCR4 peptide antagonist, enhances apoptosis and inhibits primary tumor growth and metastasis in breast cancer. *J. Cancer Ther.* **2013**, *4*, 898–906. [CrossRef]

129. Huang, M.B.; Giesler, K.E.; Katzman, B.M.; Prosser, A.R.; Truax, V.; Liotta, D.C.; Wilson, L.J.; Bond, V.C. Small molecule CXCR4 antagonists block the HIV-1 Nef/CXCR4 axis and selectively initiate the apoptotic program in breast cancer cells. *Oncotarget* **2018**, *9*, 16996–17013. [CrossRef]

130. Katkoori, V.R.; Basson, M.D.; Bond, V.C.; Manne, U.; Bumpers, H.L. Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial-to-mesenchymal transition in colon and breast cancers. *Oncotarget* **2015**, *6*, 27763–27777. [CrossRef]

131. Yang, Q.; Chen, C.; Yang, Z.; Gao, Y.; Tang, J. Suppression of breast cancer proliferation and induction of apoptosis via AKT and ERK1/2 signal transduction pathways by synthetic polypeptide derived from viral macrophage inflammatory protein II. *J. Huazhong Univ. Sci. Technol.* **2011**, *31*, 497–503. [CrossRef]

132. Yang, Q.; Zhang, F.; Ding, Y.; Huang, J.; Chen, S.; Wu, Q.; Wang, Z.; Wang, Z.; Chen, C. Antitumour activity of the recombination polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer. *Br. J. Cancer* **2014**, *110*, 1288–1297. [CrossRef] [PubMed]

133. Huang, E.H.; Singh, B.; Cristofanilli, M.; Gelovani, J.; Wei, C.; Vincent, L.; Cook, K.R.; Lucci, A. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. *J. Surg. Res.* **2009**, *155*, 231–236. [CrossRef] [PubMed]

134. Richert, M.M.; Vaidya, K.S.; Mills, C.N.; Wong, D.; Korz, W.; Hurst, D.R.; Welch, D.R. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. *Oncol. Rep.* **2009**, *21*, 761–767. [PubMed]

135. Hassan, S.; Buchanan, M.; Jahan, K.; Aguilar-Mahecha, A.; Gaboury, L.; Muller, W.J.; Alsawafi, Y.; Mourskaia, A.A.; Siegel, P.M.; Salvucci, O.; et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. *Int. J. Cancer* **2011**, *129*, 225–232. [CrossRef] [PubMed]

136. Bachelder, R.E.; Wendt, M.A.; Mercurio, A.M. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. *Cancer Res.* **2002**, *62*, 7203–7206.

137. Peng, S.B.; Zhang, X.; Paul, D.; Kays, L.M.; Gough, W.; Stewart, J.; Uhlik, M.T.; Chen, Q.; Hui, Y.H.; Zamek-Gliszczynski, M.J.; et al. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. *Mol. Cancer Ther.* **2015**, *14*, 480–490. [CrossRef]

138. Ling, X.; Spaeth, E.; Chen, Y.; Shi, Y.; Zhang, W.; Schober, W.; Hail, N., Jr.; Konopleva, M.; Andreeff, M. The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo. *PLoS ONE* **2013**, *8*, e58426. [CrossRef]

139. Pusic, I.; DiPersio, J.F. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. *Curr. Opin. Hematol.* **2010**, *17*, 319–326. [CrossRef]

140. Rosenkilde, M.M.; Gerlach, L.O.; Jakobsen, J.S.; Skerlj, R.T.; Bridgers, G.J.; Schwartz, T.W. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: Transfer of binding site to the CXCR3 receptor. *J. Biol. Chem.* **2004**, *279*, 3033–3041. [CrossRef]

141. Liu, X.; Xiao, Q.; Bai, X.; Yu, Z.; Sun, M.; Zhao, H.; Mi, X.; Wang, E.; Yao, W.; Jin, F.; et al. Activation of STAT3 is involved in malignancy mediated by CXCL12-CXCR4 signaling in human breast cancer. *Oncol. Rep.* **2014**, *32*, 2760–2768. [CrossRef]

142. Greco, S.J.; Patel, S.A.; Bryan, M.; Pliner, L.F.; Banerjee, D.; Rameshwar, P. AMD3100-mediated production of interleukin-1 from mesenchymal stem cells is key to chemosensitivity of breast cancer cells. *Am. J. Cancer Res.* **2011**, *1*, 701–715. [PubMed]

143. Tverdal, A.; Stensvold, I.; Solvoll, K.; Foss, O.P.; Lund-Larsen, P.; Bjartveit, K. Coffee consumption and death from coronary heart disease in middle aged Norwegian men and women. *BMJ* **1990**, *300*, 566–569. [CrossRef]

144. Cronin, P.A.; Wang, J.H.; Redmond, H.P. Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4. *BMC Cancer* **2010**, *10*, 225. [CrossRef]

145. Smith, M.C.; Luker, K.E.; Garbow, J.R.; Prior, J.L.; Jackson, E.; Piwnica-Worms, D.; Luker, G.D. CXCR4 regulates growth of both primary and metastatic breast cancer. *Cancer Res.* **2004**, *64*, 8604–8612. [CrossRef] [PubMed]

146. Stuelten, C.H.; Cervoni-Curet, F.N.; Busch, J.I.; Sutton, E.; Webster, J.D.; Kavalukas, S.L.; Wakefield, L.M.; Barbul, A.; Niederhuber, J.E. SDF-1α mediates wound-promoted tumor growth in a syngeneic orthotopic mouse model of breast cancer. *PLoS ONE* **2013**, *8*, e60919. [CrossRef] [PubMed]

147. Zhou, K.X.; Xie, L.H.; Peng, X.; Guo, Q.M.; Wu, Q.Y.; Wang, W.H.; Zhang, G.L.; Wu, J.F.; Zhang, G.J.; Du, C.W. CXCR4 antagonist AMD3100 enhances the response of MDA-MB-231 triple-negative breast cancer cells to ionizing radiation. *Cancer Lett.* **2018**, *418*, 196–203. [CrossRef]

148. Xiang, J.; Hurchla, M.A.; Fontana, F.; Su, X.; Amend, S.R.; Esser, A.K.; Douglas, G.J.; Mudalagiriyappa, C.; Luker, K.E.; Pluard, T.; et al. CXCR4 protein epitope mimetic antagonist POL5551 disrupts metastasis and enhances chemotherapy effect in triple-negative breast cancer. *Mol. Cancer Ther.* **2015**, *14*, 2473–2485. [CrossRef] [PubMed]

149. Kashyap, M.K.; Kumar, D.; Jones, H.; Amaya-Chanaga, C.I.; Choi, M.Y.; Melo-Cardenas, J.; Ale-Ali, A.; Kuhne, M.R.; Sabbatini, P.; Cohen, L.J.; et al. Ulocuplumab (BMS-936564/MDX1338): A fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. *Oncotarget* **2016**, *7*, 2809–2822. [CrossRef] [PubMed]

150. Velasco-Velázquez, M.; Xolalpa, W.; Pestell, R.G. The potential to target CCL5/CCR5 in breast cancer. *Expert Opin. Ther. Targets* **2014**, *18*, 1265–1275. [CrossRef]

151. Velasco-Velázquez, M.; Jiao, X.; De La Fuente, M.; Pestell, T.G.; Ertel, A.; Lisanti, M.P.; Pestell, R.G. CCR5 antagonist blocks metastasis of basal breast cancer cells. *Cancer Res.* **2012**, *72*, 3839–3850. [CrossRef] [PubMed]

152. Woollard, S.M.; Kanmogne, G.D. Maraviroc: A review of its use in HIV infection and beyond. *Drug Des. Devel. Ther.* **2015**, *9*, 5447–5468. [PubMed]

153. Tan, Q.; Zhu, Y.; Li, J.; Chen, Z.; Han, G.W.; Kufareva, I.; Li, T.; Ma, L.; Fenalti, G.; Li, J.; et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor marivoc complex. *Science* **2013**, *341*, 1387–1390. [CrossRef] [PubMed]

154. Klibanov, O.M. Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection. *Curr. Opin. Investig. Drugs* **2009**, *10*, 845–859. [PubMed]

155. Sax, M.J.; Gasch, C.; Athota, V.R.; Freeman, R.; Rasighaemi, P.; Westcott, D.E.; Day, C.J.; Nikolic, I.; Elsworth, B.; Wei, M.; et al. Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer. *Oncotarget* **2016**, *7*, 85437–85449. [CrossRef]

156. Jiao, X.; Velasco-Velázquez, M.A.; Wang, M.; Li, Z.; Rui, H.; Peck, A.R.; Korkola, J.E.; Chen, X.; Xu, S.; DuHadaway, J.B.; et al. CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion. *Cancer Res.* **2018**, *78*, 1657–1671. [CrossRef] [PubMed]

157. Yu, S.; Sun, L.; Jiao, Y.; Lee, L.T.O. The role of G protein-coupled receptor kinases in cancer. *Int. J. Biol. Sci.* **2018**, *14*, 189–203. [CrossRef] [PubMed]

158. Rajbhandari, P.; Schalper, K.A.; Solodin, N.M.; Ellison-Zelski, S.J.; Ping Lu, K.; Rim, D.L.; Alarid, E.T. Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation. *Oncogene* **2014**, *33*, 1438–1447. [CrossRef]

159. Nogués, L.; Reglero, C.; Rivas, V.; Salcedo, A.; Lafarga, V.; Neves, M.; Ramos, P.; Mendiola, M.; Berjón, A.; Stamatakis, K.; et al. G protein-coupled receptor kinase 2 (GRK2) promotes breast tumorigenesis through a HDAC6-Pin1 axis. *EBioMedicine* **2016**, *13*, 132–145. [CrossRef]

160. Thal, D.M.; Yeow, R.Y.; Schoenau, C.; Huber, J.; Tesmer, J.J. Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors. *Mol. Pharmacol.* **2011**, *80*, 294–303. [CrossRef]

161. Homan, K.T.; Larimore, K.M.; Elkins, J.M.; Szklarz, M.; Knapp, S.; Tesmer, J.J.G. Identification and structure-function analysis of subfamily selective G protein coupled receptor kinase inhibitors. *ACS Chem. Biol.* **2015**, *10*, 310–319. [CrossRef]

162. Billard, M.J.; Fitzhugh, D.J.; Parker, J.S.; Brozowski, J.M.; McGinnis, M.W.; Timoshchenko, R.G.; Serafin, D.S.; Lininger, R.; Klauber-Demore, N.; Sahagian, G.; et al. G protein coupled receptor kinase 3 regulates breast cancer migration, invasion, and metastasis. *PLoS ONE* **2016**, *11*, e0152856. [CrossRef] [PubMed]

163. George, A.J.; Thomas, W.G.; Hannan, R.D. The renin-angiotensin system and cancer: Old dog, new tricks. *Nat. Rev. Cancer* **2010**, *10*, 745–759. [CrossRef] [PubMed]

164. Nouet, S.; Nahmias, C. Signal transduction from the angiotensin II AT2 receptor. *Trends Endocrinol. Metab.* **2000**, *11*, 1–6. [CrossRef]

165. Deshayes, F.; Nahmias, C. Angiotensin receptors: A new role in cancer? *Trends Endocrinol. Metab.* **2005**, *16*, 293–299. [CrossRef]

166. Rhodes, D.R.; Ateeq, B.; Cao, Q.; Tomlins, S.A.; Mehra, R.; Laxman, B.; Kalyana-Sundaram, S.; Lonigro, R.J.; Helgeson, B.E.; Bhojani, M.S.; et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 10284–10289. [CrossRef]

167. Ishikane, S.; Takahashi-Yanaga, F. The role of angiotensin II in cancer metastasis: Potential of renin-angiotensin system blockade as a treatment for cancer metastasis. *Biochem. Pharmacol.* **2018**, *151*, 96–103. [CrossRef]

168. Stergiou, G.S.; Skeva, I.I. Renin-angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor: Similarities and differences. *Curr. Top. Med. Chem.* **2004**, *4*, 473–481. [CrossRef]

169. Bhuiyan, M.A.; Ishiguro, M.; Hossain, M.; Nakamura, T.; Ozaki, M.; Miura, S.; Nagatomo, T. Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling. *Life Sci.* **2009**, *85*, 136–140. [CrossRef]

170. Bhuiyan, M.A.; Shahriar, M.; Nagatomo, T. Binding Affinity of Candesartan, Losartan, Telmisartan and Valsartan with Angiotensin II Receptor 1 Subtype. *Bangladesh Pharm. J.* **2013**, *16*, 10–14. [CrossRef]

171. Chen, X.; Meng, Q.; Zhao, Y.; Liu, M.; Li, D.; Yang, Y.; Sun, L.; Sui, G.; Cai, L.; Dong, X. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. *Cancer Lett.* **2013**, *328*, 318–324. [CrossRef]

172. Muscella, A.; Greco, S.; Elia, M.G.; Storelli, C.; Marsigliante, S. Angiotensin II stimulation of Na+/K+ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells. *J. Endocrinol.* **2002**, *173*, 315–323. [CrossRef] [PubMed]

173. Coulson, R.; Liew, S.H.; Connelly, A.A.; Yee, N.S.; Deb, S.; Kumar, B.; Vargas, A.C.; O'Toole, S.A.; Parslow, A.C.; Poh, A.; et al. The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. *Oncotarget* **2017**, *8*, 18640–18656. [CrossRef] [PubMed]

174. Diop-Frimpong, B.; Chauhan, V.P.; Krane, S.; Boucher, Y.; Jain, R.K. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 2909–2914. [CrossRef] [PubMed]

175. Hu, C.; Liu, X.; Ran, W.; Meng, J.; Zhai, Y.; Zhang, P.; Yin, Q.; Yu, H.; Zhang, Z.; Li, Y. Regulating cancer associated fibroblasts with losartan-loaded injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and lung metastasis of triple negative breast cancer. *Biomaterials* **2017**, *144*, 60–72. [CrossRef]

176. Xia, T.; He, Q.; Shi, K.; Wang, Y.; Yu, Q.; Zhang, L.; Zhang, Q.; Gao, H.; Ma, L.; Liu, J. Losartan loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with pH sensitive peptides by inhibition of collagen in breast cancer. *Pharm. Dev. Technol.* **2018**, *1*, 13–21. [CrossRef] [PubMed]

177. Namazi, S.; Rostami-Yalmeh, J.; Sahebi, E.; Jaberipour, M.; Razmkhah, M.; Hosseini, A. The role of captopril and losartan in prevention and regression of tamoxifen-induced resistance of breast cancer cell line MCF-7: An in vitro study. *Biomed. Pharmacother.* **2014**, *68*, 565–571. [CrossRef] [PubMed]

178. Kociecka, B.; Surazynski, A.; Miltyk, W.; Palka, J. The effect of telmisartan on collagen biosynthesis depends on the status of estrogen activation in breast cancer cells. *Eur. J. Pharmacol.* **2010**, *628*, 51–56. [CrossRef]

179. Du, N.; Feng, J.; Hu, L.J.; Sun, X.; Sun, H.B.; Zhao, Y.; Yang, Y.P.; Ren, H. Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling. *Oncol. Rep.* **2012**, *27*, 1893–1903.

180. Millar, R.P.; Lu, Z.L.; Pawson, A.J.; Flanagan, C.A.; Morgan, K.; Maudsley, S.R. Gonadotropin-releasing hormone receptors. *Endocr. Rev.* **2004**, *25*, 235–275. [CrossRef]

181. Schally, A.V. Luteinizing hormone-releasing hormone analogs: Their impact on the control of tumorigenesis. *Peptides* **1999**, *20*, 1247–1262. [CrossRef]

182. Cheng, C.K.; Leung, P.C. Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. *Endocr Rev.* **2005**, *26*, 283–306. [CrossRef] [PubMed]

183. Montagnani, M.M.; Moretti, R.M.; Januszkiewicz-Caulier, J.; Motta, M.; Limonta, P. Gonadotropin-releasing hormone (GnRH) receptors in tumors: A new rationale for the therapeutical application of GnRH analogs in cancer patients? *Curr. Cancer Drug Targets* **2006**, *6*, 257–269.

184. Tan, S.H.; Wolff, A.C. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer. *Clin. Breast Cancer* **2007**, *76*, 455–464. [CrossRef] [PubMed]

185. Klijn, J.G.; de Jong, F.H.; Lamberts, S.W.; Blankenstein, M.A. LHRH-agonist treatment in clinical and experimental human breast cancer. *J. Steroid Biochem.* **1985**, *23*, 867–873. [CrossRef]

186. Lissoni, P.; Barni, S.; Crispino, S.; Cattaneo, G.; Tancini, G. Endocrine and clinical effects of an LHRH analogue in pretreated advanced breast cancer. *Tumori* **1988**, *74*, 303–308. [CrossRef]

187. Dowsett, M.; Mehta, A.; Mansi, J.; Smith, I.E. A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients. *Br. J. Cancer* **1990**, *62*, 834–837. [CrossRef] [PubMed]

188. Taylor, C.W.; Green, S.; Dalton, W.S.; Martino, S.; Rector, D.; Ingle, J.N.; Robert, N.J.; Budd, G.T.; Paradelo, J.C.; Natale, R.B.; et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An intergroup study. *J. Clin. Oncol.* **1998**, *16*, 994–999. [CrossRef]

189. Klijn, J.G.; Blamey, R.W.; Boccardo, F.; Tominaga, T.; Duchateau, L.; Sylvester, R. Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. *J. Clin. Oncol.* **2001**, *19*, 343–353.

190. Flanagan, C.A.; Millar, R.P.; Illing, N. Advances in understanding gonadotrophin-releasing hormone receptor structure and ligand interaction. *Rev. Reprod.* **1997**, *2*, 113–120. [CrossRef]

191. Pappa, E.V.; Zompra, A.A.; Spyranti, Z.; Diamantopoulou, Z.; Pairas, G.; Lamari, F.N.; Katsoris, P.; Spyroulias, G.A.; Cordopatis, P. Enzymatic stability, solution structure, and antiproliferative effect on prostate cancer cells of leuprolide and new gonadotrophin-releasing hormone peptide analogs. *Pept. Sci.* **2011**, *96*, 260–272. [CrossRef]

192. Stein, R.C.; Dowsett, M.; Hedley, A.; Gazet, J.C.; Ford, H.T.; Coombes, R.C. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. *Br. J. Cancer* **1990**, *62*, 679–683. [CrossRef]

193. Celio, L.; Martinetti, A.; Ferrari, L.; Buzzoni, R.; Mariani, L.; Miceli, R.; Seregni, E.; Procopio, G.; Cassata, A.; Bombardieri, E.; et al. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study. *Anticancer Res.* **1999**, *19*, 2261–2268.

194. Rody, A.; Loibl, S.; von Minckwitz, G.; Kaufmann, M. Use of goserelin in the treatment of breast cancer. *Expert Rev. Anticancer Ther.* **2005**, *5*, 591–604. [CrossRef] [PubMed]

195. Mitchell, H. Goserelin ('Zoladex')—Offering patients more choice in early breast cancer. *Eur. J. Oncol. Nurs.* **2004**, *2*, S95–S103. [CrossRef] [PubMed]

196. Engel, J.B.; Schally, A.V. Drug Insight: Clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. *Nat. Clin. Pract. Endocrinol. Metab.* **2007**, *3*, 157–167. [CrossRef] [PubMed]

197. Tan, O.; Bukulmez, O. Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists. *Curr. Opin. Obstet. Gynecol.* **2011**, *23*, 238–244. [CrossRef] [PubMed]

198. Patrick, E.; Whitson, M.; Smith, A.; Parnell, J.; Thomas, S.E.; Blankenship, C.C. GnRH receptor antagonists for prostate cancer. *JAAPA* **2013**, *26*, 51–52. [CrossRef] [PubMed]

199. Guo, Z.; Zhu, Y.F.; Gross, T.D.; Tucci, F.C.; Gao, Y.; Moorjani, M.; Connors, P.J., Jr.; Rowbottom, M.W.; Chen, Y.; Struthers, S.; et al. Synthesis and structure-activity relationships of 1-arylmethyl-5-aryl-6-methyluracils as potent gonadotrophin-releasing hormone receptor antagonists. *J. Med. Chem.* **2004**, *47*, 1259–1271. [CrossRef]

200. Bonger, K.M.; van den Berg, R.J.B.H.N.; Knijnenburg, A.D.; Heitman, L.H.; IJzerman, A.P.; Oosterom, J.; Timmers, C.M.; Overkleeft, H.S.; van der Marel, G.A. Synthesis and evaluation of homodimeric GnRHR antagonists having a rigid bis-propargylated benzene core. *Bioorg. Med. Chem.* **2008**, *16*, 3744–3758. [CrossRef]

201. Tukun, F.L.; Olberg, D.E.; Riss, P.J.; Haraldsen, I.; Kaass, A.; Klaveness, J. Recent development of non-peptide GnRH antagonists. *Molecules* **2017**, *22*, 2188. [CrossRef]

202. Rosenkulde, M.M.; Cahir, M.; Gether, U.; Hjorth, S.A.; Schwartz, T.W. Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding. *J. Biol. Chem.* **1994**, *269*, 28160–28164.

203. Zhou, W.; Rodic, V.; Kitanovic, S.; Flanagan, C.A.; Chi, L.; Weinstein, H.; Maayani, S.; Millar, R.P.; Sealfon, S.C. A locus of the gonadotropin-releasing hormone receptor that differentiates agonist and antagonist binding sites. *J. Biol. Chem.* **1995**, *270*, 18853–18857. [CrossRef]

204. Patel, Y.C. Somatostatin and its receptor family. *Front. Neuroendocrinol.* **1999**, *20*, 157–198. [CrossRef]

205. Bousquet, C.; Puente, E.; Buscail, L.; Vaysse, N.; Susini, C. Antiproliferative effect of somatostatin and analogs. *Chemotherapy* **2001**, *47*, 30–39. [CrossRef]

206. Watt, H.L.; Kharmate, G.; Kumar, U. Biology of somatostatin in breast cancer. *Mol. Cell. Endocrinol.* **2008**, *286*, 251–261. [CrossRef]

207. Fani, M.; Nicolas, G.P.; Wild, D. Somatostatin receptor antagonists for imaging and therapy. *J. Nucl. Med.* **2017**, *58*, 61S–66S. [CrossRef]

208. Ruscica, M.; Arvigo, M.; Steffani, L.; Ferone, D.; Magni, P. Somatostatin, somatostatin analogs and somatostatin receptor dynamics in the biology of cancer progression. *Curr. Mol. Med.* **2013**, *13*, 555–571. [CrossRef]

209. Díez, M.; Teulé, A.; Salazar, R. Gastroenteropancreatic neuroendocrine tumors: Diagnosis and treatment. *Ann. Gastroenterol.* **2013**, *26*, 29–36.

210. Costa, F.; Gumz, B. Octreotide—A Review of its use in treating neuroendocrine tumours. *Eur. Endocrinol.* **2014**, *10*, 70–74. [CrossRef]

211. Gadelha, M.R.; Wildemberg, L.E.; Bronstein, M.D.; Gatto, F.; Ferone, D. Somatostatin receptor ligands in the treatment of acromegaly. *Pituitary* **2017**, *20*, 100–108. [CrossRef]

212. Weckbecker, G.; Liu, R.; Tolcsvai, L.; Bruns, C. Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. *Cancer Res.* **1992**, *52*, 4973–4978.

213. Huang, C.M.; Wu, Y.T.; Chen, S.T. Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. *Chem. Biol.* **2000**, *7*, 453–461. [CrossRef]

214. Hruby, V.J. Designing peptide receptor agonists and antagonists. *Nat. Rev. Drug Discov.* **2002**, *1*, 847–858. [CrossRef]

215. Prévost, G.; Foehrlé, E.; Thomas, F.; Pihan, I.; Veber, N.; Starzec, A.; Israël, L. Growth of human breast cancer cell lines is inhibited by the somatostatin analog BIM23014. *Endocrinology* **1991**, *129*, 323–329. [CrossRef]

216. Kahán, Z.; Nagy, A.; Schally, A.V.; Hebert, F.; Sun, B.; Groot, K.; Halmos, G. Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. *Int. J. Cancer* **1999**, *82*, 592–598. [CrossRef]

217. Seitz, S.; Schally, A.V.; Treszl, A.; Papadia, A.; Rick, F.; Szalontay, L.; Szepeshazi, K.; Ortmann, O.; Halmos, G.; Hohla, F.; et al. Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition. *Anticancer Drugs* **2009**, *20*, 553–558. [CrossRef]

218. Feng, Q.; Yu, M.Z.; Wang, J.C.; Hou, W.J.; Gao, L.Y.; Ma, X.F.; Pei, X.W.; Niu, Y.J.; Liu, X.Y.; Qiu, C.; et al. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles. *Biomaterials* **2014**, *35*, 5028–5038. [CrossRef]

219. O'Byrne, K.J.; Dobbs, N.; Propper, D.J.; Braybrooke, J.P.; Koukourakis, M.I.; Mitchell, K.; Woodhull, J.; Talbot, D.C.; Schally, A.V.; Harris, A.L. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. *Br. J. Cancer* **1999**, *79*, 1413–1418. [CrossRef]

220. Dolan, J.T.; Miltenburg, D.M.; Granchi, T.S.; Miller, C.C., 3rd; Brunicardi, F.C. Treatment of metastatic breast cancer with somatostatin analogues—A meta-analysis. *Ann. Surg. Oncol.* **2001**, *8*, 227–233.

221. Van Essen, M.; Krenning, E.P.; De Jong, M.; Valkema, R.; Kwekkeboom, D.J. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. *Acta Oncol.* **2007**, *46*, 723–734. [CrossRef]

222. Laverman, P.; Sosabowski, J.K.; Boerman, O.C.; Oyen, W.J. Radiolabelled peptides for oncological diagnosis. *Eur. J. Nucl. Med. Mol. Imaging* **2012**, *39*, S78–S92. [CrossRef]

223. Smith-Jones, P.M.; Bischof, C.; Leimer, M.; Gludovacz, D.; Angelberger, P.; Pangerl, T.; Peck-Radosavljevic, M.; Hamilton, G.; Kaserer, K.; Kofler, A.; et al. DOTA-lanreotide: A novel somatostatin analog for tumor diagnosis and therapy. *Endocrinology* **1999**, *140*, 5136–5148. [CrossRef]

224. Ischia, J.; Patel, O.; Shulkes, A.; Baldwin, G.S. Gastrin-releasing peptide: Different forms, different functions. *Biofactors* **2009**, *35*, 69–75. [CrossRef]

225. Van de Wiele, C.; Dumont, F.; van Belle, S.; Slegers, G.; Peers, S.H.; Dierckx, R.A. Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumour imaging? *Nucl. Med. Commun.* **2001**, *22*, 5–15. [CrossRef]

226. Smith, C.J.; Volkert, W.A.; Hoffman, T.J. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: A concise update. *Nucl. Med. Biol.* **2003**, *30*, 861–868. [CrossRef]

227. Parry, J.J.; Andrews, R.; Rogers, B.E. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. *Breast Cancer Res. Treat.* **2007**, *101*, 175–183. [CrossRef]

228. Dalm, S.U.; Martens, J.W.; Sieuwerts, A.M.; van Deurzen, C.H.; Koelewijn, S.J.; de Blois, E.; Maina, T.; Nock, B.A.; Brunel, L.; Fehrentz, J.A.; et al. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer. *J. Nucl. Med.* **2015**, *56*, 752–757. [CrossRef]

229. Prignon, A.; Nataf, V.; Provost, C.; Cagnolini, A.; Montravers, F.; Gruaz-Guyon, A.; Lantry, L.E.; Talbot, J.N.; Nunn, A.D. (68)Ga-AMBA and (18)F-FDG for preclinical PET imaging of breast cancer: Effect of tamoxifen treatment on tracer uptake by tumor. *Nucl. Med. Biol.* **2015**, *42*, 92–98. [CrossRef]

230. Maina, T.; Bergsma, H.; Kulkarni, H.R.; Mueller, D.; Charalambidis, D.; Krenning, E.P.; Nock, B.A.; de Jong, M.; Baum, R.P. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [^{68}Ga]SB3 and PET/CT. *Eur. J. Nucl. Med. Mol. Imaging* **2016**, *43*, 964–973. [CrossRef]

231. Morgat, C.; MacGrogan, G.; Brouste, V.; Vélasco, V.; Sévenet, N.; Bonnefoi, H.; Fernandez, P.; Debled, M.; Hindié, E. Expression of gastrin-releasing peptide receptor in breast cancer and its association with pathologic, biologic, and clinical parameters: A study of 1432 primary tumors. *J. Nucl. Med.* **2017**, *58*, 1401–1407. [CrossRef]

232. Vangsted, A.J.; Andersen, E.V.; Nedergaard, L.; Zeuthen, J. Gastrin releasing peptide GRP(14-27) in human breast cancer cells and in small cell lung cancer. *Breast Cancer Res. Treat.* **1991**, *19*, 119–128. [CrossRef] [PubMed]

233. Patel, O.; Shulkes, A.; Baldwin, G.S. Gastrin-releasing peptide and cancer. *Biochim. Biophys. Acta* **2006**, *1766*, 23–41. [CrossRef] [PubMed]

234. Shirahige, Y.; Cai, R.Z.; Szepeshazi, K.; Halmos, G.; Pinski, J.; Groot, K.; Schally, A.V. Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice. *Biomed. Pharmacother.* **1994**, *48*, 465–472. [CrossRef]

235. Miyazaki, M.; Lamharzi, N.; Schally, A.V.; Halmos, G.; Szepeshazi, K.; Groot, K.; Cai, R.Z. Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095. *Eur. J. Cancer* **1998**, *34*, 710–717. [CrossRef]

236. Kahán, Z.; Sun, B.; Schally, A.V.; Arencibia, J.M.; Cai, R.Z.; Groot, K.; Halmos, G. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II. *Cancer* **2000**, *88*, 1384–1392. [CrossRef]

237. Davenport, A.P.; Hyndman, K.A.; Dhaun, N.; Southan, C.; Kohan, D.E.; Pollock, J.S.; Pollock, D.M.; Webb, D.J.; Maguire, J.J. Endothelin. *Pharmacol. Rev.* **2016**, *68*, 357–418. [CrossRef] [PubMed]

238. Rosanò, L.; Spinella, F.; Bagnato, A. Endothelin 1 in cancer: Biological implications and therapeutic opportunities. *Nat. Rev. Cancer* **2013**, *13*, 637–651. [CrossRef]

239. Wülfing, P.; Diallo, R.; Kersting, C.; Wülfing, C.; Poremba, C.; Rody, A.; Greb, R.R.; Böcker, W.; Kiesel, L. Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. *Clin. Cancer Res.* **2003**, *9*, 4125–4131.

240. Wülfing, P.; Kersting, C.; Tio, J.; Fischer, R.J.; Wülfing, C.; Poremba, C.; Diallo, R.; Böcker, W.; Kiesel, L. Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer. *Clin. Cancer Res.* **2004**, *10*, 2393–2400. [CrossRef]

241. Wülfing, P.; Tio, J.; Kersting, C.; Sonntag, B.; Buerger, H.; Wülfing, C.; Euler, U.; Boecker, W.; Tulusan, A.H.; Kiesel, L. Expression of endothelin-A-receptor predicts unfavourable response to neoadjuvant chemotherapy in locally advanced breast cancer. *Br. J. Cancer* **2004**, *91*, 434–440. [CrossRef]

242. Bagnato, A.; Rosanò, L. The endothelin axis in cancer. *Int. J. Biochem. Cell Biol.* **2008**, *40*, 1443–1451. [CrossRef] [PubMed]

243. Smollich, M.; Götte, M.; Kersting, C.; Fischgräbe, J.; Kiesel, L.; Wülfing, P. Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion. *Breast Cancer Res. Treat.* **2008**, *108*, 175–182. [CrossRef] [PubMed]

244. Fischgräbe, J.; Götte, M.; Michels, K.; Kiesel, L.; Wülfing, P. Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells. *Int. J. Cancer* **2010**, *127*, 696–706. [CrossRef] [PubMed]

245. Smollich, M.; Götte, M.; Fischgräbe, J.; Macedo, L.F.; Brodie, A.; Chen, S.; Radke, I.; Kiesel, L.; Wülfing, P. ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole. *Breast Cancer Res. Treat.* **2010**, *123*, 345–357. [CrossRef] [PubMed]

246. Jewell, A.N.; Swamydas, M.; Castillo, C.I.; Wyan, H.; Allen, L.D.; McDermott, K.A.; Eddy, J.M.; Dréau, D. The endothelin axis stimulates the expression of pro-inflammatory cytokines and pro-migratory molecules in breast cancer. *Cancer Investig.* **2010**, *28*, 932–943. [CrossRef] [PubMed]

247. Bolli, M.H.; Boss, C.; Binkert, C.; Buchmann, S.; Bur, D.; Hess, P.; Iglarz, M.; Meyer, S.; Rein, J.; Rey, M.; et al. The discovery of *N*-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-*N′*-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. *J. Med. Chem.* **2012**, *55*, 7849–7861. [CrossRef] [PubMed]

248. Lee, H.J.; Hanibuchi, M.; Kim, S.J.; Yu, H.; Kim, M.S.; He, J.; Langley, R.R.; Lehembre, F.; Regenass, U.; Fidler, I.J. Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel. *Neuro-Oncol.* **2016**, *18*, 486–496. [CrossRef]

249. Wu, F.; Zhang, Y.; Sun, B.; McMahon, A.P.; Wang, Y. Hedgehog signaling: From basic biology to cancer therapy. *Cell Chem. Biol.* **2017**, *24*, 252–280. [CrossRef]

250. Harris, P.J.; Speranza, G.; Dansky Ullmann, C. Targeting embryonic signaling pathways in cancer therapy. *Expert Opin. Ther. Targets* **2012**, *16*, 131–145. [CrossRef]

251. Hui, M.; Cazet, A.; Nair, R.; Watkins, D.N.; O'Toole, S.A.; Swarbrick, A. The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. *Breast Cancer Res.* **2013**, *15*, 203. [CrossRef]

252. O'Toole, S.A.; Machalek, D.A.; Shearer, R.F.; Millar, E.K.; Nair, R.; Schofield, P.; McLeod, D.; Cooper, C.L.; McNeil, C.M.; McFarland, A.; et al. Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. *Cancer Res.* **2011**, *71*, 4002–4014. [CrossRef] [PubMed]

253. Ramaswamy, B.; Lu, Y.; Teng, K.Y.; Nuovo, G.; Li, X.; Shapiro, C.L.; Majumder, S. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. *Cancer Res.* **2012**, *72*, 5048–5059. [CrossRef] [PubMed]

254. Benvenuto, M.; Masuelli, L.; De Smaele, E.; Fantini, M.; Mattera, R.; Cucchi, D.; Bonanno, E.; Di Stefano, E.; Frajese, G.V.; Orlandi, A.; et al. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors. *Oncotarget* **2016**, *7*, 9250–9270. [CrossRef] [PubMed]

255. Di Mauro, C.; Rosa, R.; D'Amato, V.; Ciciola, P.; Servetto, A.; Marciano, R.; Orsini, R.C.; Formisano, L.; De Falco, S.; Cicatiello, V.; et al. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. *Br. J. Cancer* **2017**, *116*, 1425–1435. [CrossRef] [PubMed]

256. Martín, M.; Ruiz-Borrego, M.; Trigo Perez, J.M.; Antolín, S.; García-Sánez, J.A.; Corral, J.; Jerez, Y.; Urruticoechea, A.; Colom, H.; Gonzalo, N.; et al. A phase I study of sonidegib (S) in combination with docetaxel (D) in patients (pts) with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study). *Ann. Oncol.* **2016**, *27*, 281P. [CrossRef]

257. Cazet, A.S.; Hui, M.N.; Elsworth, B.L.; Wu, S.Z.; Roden, D.; Chan, C.L.; Skhinas, J.N.; Collot, R.; Yang, J.; Harvey, K.; et al. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. *Nat. Commun.* **2018**, *9*, 2897. [CrossRef] [PubMed]

258. Stathis, A.; Hess, D.; von Moos, R.; Homicsko, K.; Griguolo, G.; Joerger, M.; Mark, M.; Ackermann, C.J.; Allegrini, S.; Catapano, C.V.; et al. Swiss Group for Clinical Cancer Research (SAKK). Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. *Investig. New Drugs* **2017**, *35*, 766–772. [CrossRef]

259. Ruiz-Borrego, M.; Jimenez, B.; Antolín, S.; García-Saenz, J.A.; Corral, J.; Jerez, Y.; Trigo, J.; Urruticoechea, A.; Colom, H.; Gonzalo, N.; et al. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study. *Investig. New Drugs* **2018**. [CrossRef]

260. MacDonald, B.T.; Tamai, K.; He, X. Wnt/beta-catenin signaling: Components, mechanisms, and diseases. *Dev. Cell* **2009**, *17*, 9–26. [CrossRef]

261. Acebron, S.P.; Niehrs, C. β-Catenin-Independent Roles of Wnt/LRP6 Signaling. *Trends Cell Biol.* **2016**, *26*, 956–967. [CrossRef]

262. Zhan, T.; Rindtorff, N.; Boutros, M. Wnt signaling in cancer. *Oncogene* **2017**, *36*, 1461–1473. [CrossRef]

263. Lin, S.Y.; Xia, W.; Wang, J.C.; Kwong, K.Y.; Spohn, B.; Wen, Y.; Pestell, R.G.; Hung, M.C. Beta-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 4262–4266. [CrossRef]

264. De, P.; Carlson, J.H.; Wu, H.; Marcus, A.; Leyland-Jones, B.; Dey, N. Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers. *Oncotarget* **2016**, *7*, 43124–43149. [CrossRef]

265. Klarmann, G.J.; Decker, A.; Farrar, W.L. Epigenetic gene silencing in the Wnt pathway in breast cancer. *Epigenetics* **2008**, *3*, 59–63. [CrossRef]

266. Liu, C.C.; Prior, J.; Piwnica-Worms, D.; Bu, G. LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 5136–5141. [CrossRef]

267. Yang, L.; Wu, X.; Wang, Y.; Zhang, K.; Wu, J.; Yuan, Y.C.; Deng, X.; Chen, L.; Kim, C.C.; Lau, S.; et al. FZD7 has a critical role in cell proliferation in triple negative breast cancer. *Oncogene* **2011**, *30*, 4437–4446. [CrossRef]

268. Krishnamurthy, N.; Kurzrock, R. Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. *Cancer Treat. Rev.* **2018**, *62*, 50–60. [CrossRef]

269. Proffitt, K.D.; Madan, B.; Ke, Z.; Pendharkar, V.; Ding, L.; Lee, M.A.; Hannoush, R.N.; Virshup, D.M. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. *Cancer Res.* **2013**, *73*, 502–507. [CrossRef]

270. Liu, J.; Pan, S.; Hsieh, M.H.; Ng, N.; Sun, F.; Wang, T.; Kasibhatla, S.; Schuller, A.G.; Li, A.G.; Cheng, D.; et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 20224–20229. [CrossRef]

271. Liu, B.Y.; Soloviev, I.; Huang, X.; Chang, P.; Ernst, J.A.; Polakis, P.; Sakanaka, C. Mammary tumor regression elicited by Wnt signaling inhibitor requires IGFBP5. *Cancer Res.* **2012**, *72*, 1568–1578. [CrossRef]

272. Säfholm, A.; Tuomela, J.; Rosenkvist, J.; Dejmek, J.; Härkönen, P.; Andersson, T. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. *Clin. Cancer Res.* **2008**, *14*, 6556–6563. [CrossRef] [PubMed]

273. Gurney, A.; Axelrod, F.; Bond, C.J.; Cain, J.; Chartier, C.; Donigan, L.; Fischer, M.; Chaudhari, A.; Ji, M.; Kapoun, A.M.; et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 11717–11722. [CrossRef] [PubMed]